Novel optical devices, methods and systems relating to the detection of glucose, and more particularly to real-time glucose monitoring, are disclosed herein. More particularly, various hardware and methodological means are disclosed for ratiometric correction of optical glucose measurements for artifacts of optical systems.
|
1. An optical device for determining blood glucose concentration, comprising:
at least one excitation light source that emits at least one excitation light signal;
a fiber optic sensor optically coupled to the at least one excitation light source and comprising an indicator system comprising a fluorophore operably coupled to a glucose binding moiety, wherein upon absorption of at least a portion of the at least one excitation light signal, the indicator system emits at least a first emission light signal and a second emission light signal, wherein the first and second emission light signals are each related to glucose concentration, and wherein a ratio of the first and second emission light signals is glucose insensitive and the ratio is related to pH levels; and
a detector system operably coupled to at least the sensor, wherein the detector system is adapted to detect the first and second emission light signals.
2. The optical device of
3. The optical device of
4. The optical device of
5. The optical device of
6. The optical device of
7. The optical device of
8. The optical device of
9. The optical device of
10. The optical device of
11. The optical device of
12. The optical device of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Field of the Invention
In preferred embodiments, the invention relates to the detection of blood glucose, and more particularly to ratiometric correction of optical glucose measurements for potential artifacts of optical systems.
Description of the Related Art
Hyperglycemia and insulin resistance are common in critically ill patients, even if such patients have not previously had diabetes. In these situations, glucose levels rise in critically ill patients thereby increasing the risk of damage to a patient's organs. Further, studies have shown that normalization of blood glucose levels with insulin therapy improves the prognosis for such patients, thereby decreasing mortality rates.
More recent scientific evidence confirms that dramatic improvements in the clinical outcome of hospitalized Intensive Care Unit (ICU) patients can result from tight therapeutic control of blood glucose to normal ranges. These studies indicate that Tight Glycemic Control (TGC) of ICU patients may reduce mortality by as much as 40%, and significantly lower complication rates. In these situations, it is necessary to accurately, conveniently and continuously monitor blood sugar in a real-time device specifically designed to meet the challenging needs of the ICU environment. Researchers at Johns Hopkins University estimate that TGC can save as many as 150,000 lives and reduce U.S. healthcare costs by as much as $18 billion annually.
Performing TGC requires continuous and accurate monitoring of a patient's blood glucose levels. Thus, there is a need for a real-time glucose monitoring system that is adapted to meet the needs of ICU patients.
Various embodiments of optical systems and methods are disclosed herein for determining blood glucose concentrations. The various embodiments share at least two features. First, they involve exciting a chemical indicator system with an excitation light signal and measuring the emission light signal of the indicator system, wherein the indicator system comprises a fluorophore operably coupled to a glucose binding moiety—such that the emission light signal generated by the indicator system upon excitation is related to the blood glucose concentration. Second, they involve correcting the blood glucose concentration measurements from the aforementioned indicator system for potential artifacts and errors derived from the optical systems themselves, which are unrelated to the blood glucose concentration. The correcting is performed by ratiometric analysis. More particularly, the ratio of emission light signal to a second light signal that is propagated through the optical system, e.g., the excitation light signal or a separate reference light signal, is used for correcting any non-glucose related contributions of the optical system. All of the various hardware embodiments and methods disclosed herein are configured to provide optical determination and ratiometric correction of blood glucose concentration. More detailed descriptions of the many embodiments may be found in the accompanying Drawings and Detailed Description.
An optical device for determining blood glucose concentration is disclosed in accordance with preferred aspects of the present invention. The device comprises: a fiber optic sensor sized to be positioned within a blood vessel, the sensor being optically coupled to the excitation light source and comprising an indicator system comprising a fluorophore operably coupled to a glucose binding moiety, wherein upon absorption of at least a portion of the excitation light signal, the indicator system emits an emission light signal having an intensity related to the blood glucose concentration; and a light sensitive module operably coupled to at least the fiber optic sensor, wherein the light sensitive module detects the emission light signal and at least a second light signal, wherein the second light signal is derived from the excitation light source or an optional reference light source.
In preferred embodiments, the optical device further comprises a data processing device configured to determine the blood glucose concentration in the blood vessel by performing a ratiometric analysis of the emission light signal and the at least second light signal thereby substantially compensating for changes in the optical emission signal intensity unrelated to the blood glucose concentration.
In certain embodiments, the optical device for determining blood glucose concentration comprises a reference light source that emits a reference light signal. The optical device for determining blood glucose concentration can also comprise at least one optical module configured to deliver the excitation light signal and the reference light signal to the fiber optic sensor. The optical module can comprise a collimator lens, an interference filter, and/or a focusing lens for each light source.
The optical device for determining blood glucose concentration can also comprise a mode mixing scrambler configured to remove high mode light from at least the excitation light signal. The fluorophore in the optical device can be excited by the excitation light signal and emits at least a first emission light signal and a second emission light signal, wherein the first and second emission light signals are related to glucose concentrations, and wherein a ratio of the first and second emission light signals is pH insensitive.
The optical device can also comprise a second excitation light source that emits an excitation light signal at a different wavelength than the first excitation light source. In this embodiment, the fluorophore can be excited by the first and second excitation light signals and emits a single emission light.
In certain embodiments, the light sensitive module (or detector system) in the optical device comprises a beam splitter configured to receive at least the emission light signal and the excitation light signal from the fiber optic sensor, wherein the beam splitter is configured to reflect a first portion of light and configured to allow a second portion of light to pass through the beam splitter. In other embodiments, the light sensitive module (or detector system) comprises at least a first detector, a second detector, a first amplifier, a second amplifier, and a first analog to digital converter, and a second analog to digital converter. The light sensitive module (or detector system) can also comprise, in other embodiments, a microspectrometer or spectrometer.
The fiber optic sensor in the optical device can also comprise a second fluorophore, wherein upon absorption of at least a portion of the excitation light signal, the second fluorophore emits a second emission light signal having an intensity insensitive to the blood pH and glucose concentration. The fiber optic sensor in the optical device can also comprise a second optical fiber that is embedded with a dye, wherein the dye emits a second emissions light upon excitation by the excitation light signal. The fiber optic sensor can also comprise a dye coated surface that emits a second emission light upon excitation by the excitation light signal.
In certain embodiments, the optical device for determining blood glucose concentration, comprises: an excitation light source that emits an excitation light signal; a fiber optic sensor sized to be positioned within a blood vessel, the sensor being operably coupled to the excitation light source and comprising an indicator system comprising a fluorophore operably coupled to a glucose binding moiety, wherein upon absorption of at least a portion of the excitation light signal, the indicator system emits an emission light signal having an intensity related to the blood glucose concentration; and a detector system operably coupled to at least the sensor, wherein the detector system comprises a means for detecting the emission light signal and at least a second light signal, wherein the second light signal is derived from the excitation light source or an optional reference light source. The means for detecting the emission light signal and at least a second light signal can comprise a microspectrometer. In other embodiments, the means for detecting the emission light signal and at least a second light signal comprises at least two light detectors.
The optical device can also comprise a data processing device in communication with the detector system, wherein the data processing device determines the blood glucose concentration substantially corrected for artifacts of the optical device unrelated to the blood glucose concentration by performing a ratiometric analysis of the emission light signal and the second light signal.
In certain embodiments, an optical system for determining blood glucose concentration, comprises: an excitation light source that emits an excitation light signal; a fiber optic sensor sized to be positioned within a blood vessel, the sensor being operably coupled to the excitation light source and comprising an indicator system comprising a fluorophore operably coupled to a glucose binding moiety, wherein upon absorption of at least a portion of the excitation light signal, the indicator system emits an emission light signal having an intensity related to the blood glucose concentration; at least one optical module configured to deliver the excitation light signal to the fiber optic sensor and the emission light signal from the fiber optic sensor to a detector system, wherein the detector system comprises a means for detecting the emission light signal and at least a second light signal, wherein the second light signal is derived from the excitation light source or an optional reference light source; and a computer system configured to receive data from the detector system, wherein the computer system is configured to perform ratiometric calculations on the data to substantially eliminate optical artifacts unrelated to glucose concentrations, wherein the computer system comprises a monitor for outputting data to a user, an input device for allowing the user to input additional data into the computer system, a processor for performing the ratiometric calculations, a storage device for storing data, and a memory.
In certain embodiments, the means for detecting the emission light signal and at least a second light signal comprises a microspectrometer. The means for detecting the emission light signal and at least a second light signal can also comprise at least two light detectors.
A ratiometric method for correcting an optical measurement of blood glucose concentration for optical artifacts unrelated to the blood glucose concentration is disclosed in accordance with further aspects of the invention. The method comprises the steps of:
A disposable fiber optic glucose sensor, comprising an elongate member having proximal and distal end regions, wherein the proximal end region of the elongate member is configured for operably coupling to an optical device comprising an excitation light source and a detector, and wherein the distal end region of the elongate member is sized to be positioned within a blood vessel and comprises a cavity disposed therein and a reflective surface, wherein the cavity houses an indicator system comprising a fluorophore operably coupled to a glucose binding moiety immobilized within a hydrogel configured to be permeable to glucose in the blood vessel, such that upon excitation with an excitation light signal from the excitation light source, the indicator system emits an emission light signal having an intensity related to a blood glucose concentration, wherein the reflective surface is configured to reflect the emission light signal and the excitation light signal through the optical device, and the cavity comprises a design. The disposable fiber optic glucose sensor of claim 30, wherein the reflective surface is a mirror.
In one embodiment, the hydrogel in the disposable fiber optic glucose sensor is confined by a semi-permeable membrane that allows passage of glucose and blocks passage of the binding moiety. Further, the design of the cavity in the disposable fiber optic glucose sensor of claim can comprise a plurality of holes in the elongate member. In certain embodiments, the plurality of holes are positioned perpendicular to a tangent along a length of the elongate member, and wherein the plurality of holes are evenly spaced horizontally and evenly rotated around the sides of the elongate member. The plurality of holes can also be positioned at an angle to a tangent along a length of the elongate member, and wherein the plurality of holes are evenly spaced horizontally and evenly rotated around the sides of the elongate member.
In one embodiment, the design of the cavity in the disposable fiber optic glucose sensor comprises a groove along a length of the elongate member. The groove can also comprise a depth that extends to the center of the elongate member. In other embodiments, the groove spirals around the length of the elongate member. The design of the cavity can also comprise a plurality of sections cut from the elongate member. The sections can form a triangular wedge area that extends to the center of the elongate member, and the sections can be evenly spaced horizontally and evenly rotated around the sides of the elongate member.
For purposes of this summary, certain aspects, advantages, and novel features of the invention are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment of the invention. Thus, for example, those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves one advantage or group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
The foregoing and other features, aspects and advantages of the present invention are described in detail below with reference to the drawings of various embodiments, which are intended to illustrate and not to limit the invention. The drawings comprise the following figures in which:
In certain embodiments, the optical glucose measurement system measures glucose concentration levels using glucose-sensing chemical indicator systems. Such indicator systems preferably comprise a fluorophore operably coupled to a glucose binding moiety. Preferably, the glucose binding moiety acts as a quencher with respect to the fluorophore (e.g., suppresses the fluorescent emission signal of the fluorophore in response to excitation light when it associates with the fluorophore). In preferred embodiments, as the glucose binding moiety binds glucose (e.g., as glucose concentrations rise), it dissociates from the fluorophore, which then generates a fluorescent emission signal upon excitation. Accordingly, in such embodiments, the higher the glucose concentration, the more glucose bound by the binding moiety, the less quenching, and the higher the fluorescence intensity of the fluorophore upon excitation.
The optical glucose measurement system measures, in certain embodiments, the glucose concentrations intravascularly and in real-time through the use of such fluorophore-quencher indicator systems. The glucose-sensing indicator systems can be immobilized in a hydrogel. The hydrogel can be inserted into an optical fiber such that light may be transmitted through the hydrogel while at least a portion of the hydrogel is in contact with blood. The hydrogel is preferably permeable to blood and analytes, specifically glucose. The optical fiber together with the hydrogels can comprise a glucose sensor that is placed in a mammalian (human or animal) blood vessel. In certain embodiments, light is transmitted into the glucose sensor from a light source. The light source can be a light emitting diode that emits an optical excitation signal. The optical excitation signal can excite the fluorophore systems in the presence of glucose, such that the fluorophores emit light at an emission wavelength. In certain embodiments, the fluorophore systems can be configured to emit an optical emission signal at a first wavelength having an intensity related to the blood glucose concentration in the blood vessel. The light can be directed out of the glucose sensor such that the light is detected by a light sensitive module (or detector system) that can comprise at least one detector. Detectors include any component capable of converting light into a measurable signal, and may include but are not limited to photomultipliers, photodiodes, diode arrays, or the like. The at least one detector can be configured to measure the intensity of the emission wavelength because the intensity of the emission wavelength, in certain embodiments, is related to the glucose concentration present in the blood. In certain embodiments, the light sensitive module (or detector system) comprises an interference filter, an amplifier, and/or an analog-to-digital converter. The light sensitive module (or detector system) can also comprise a microspectrometer, spectrometer, or the like.
Various non-glucose related factors can effect the measurements of the intensity of the emission wavelength, resulting in measurement errors. In certain embodiments, the measurement errors are eliminated or are substantially eliminated or reduced by employing a ratio of certain signals. The measurement errors that may be eliminated include but are not limited to changes in the intensity of the light generated from the light source(s), changes in the coupling efficiency of light into the optical fibers, bending of the optical fiber and the ensuing loss of light from the fiber, changes in the sensitivity of the detection circuit due to, for example, temperature or age or duration of use. In certain embodiments, the ratio of certain signals is unaffected by changes in the light source intensity, the coupling efficiency of the light source into the optical fibers, bending of the optical fibers or the like. The ratio of certain signals can be the ratio of an emission signal to an excitation signal. In certain embodiments, the ratio of certain signals is the ratio of an emission signal to a second optical signal. The second signal may be the excitation light signal which is transmitted through the optical system, through the sensor and indicator system, and reflects back at least in part from the sensor into the light sensitive module (or detector system). Alternatively, the second signal may be generated by a separate reference light, for example red light, which is not absorbed by the indictor system. The second signal may be generated by certain fluorophores as a second emission signal at a different wavelength—the intensity of which is independent of glucose. Any light that is propagated through the optical system, can be either not altered by the glucose concentration or is the excitation light. Light not altered by the glucose concentration can be detected by the light sensitive system (or detector system) and may be used as the second or reference light signal.
From the disclosure herein, it will be apparent to those of ordinary skill in the art that other sources of measurement errors may also be eliminated by employing a ratio of certain of certain signals.
With reference to
The interference filter 103 can block a portion of the spectrum of each light that is transmitted from the light sources 101. In certain embodiments, the interference filter 103 blocks the portion of spectrum that overlaps with the emission wavelength generated from the fluorophore systems. For example, if a system that employs a blue excitation light to produce a green emission, then an interference filter is preferably used to narrow the band of blue excitation, because the blue excitation light may comprise both blue and green light. An unfiltered excitation blue that comprises green light can produce inaccurate green emission signal because the green light from the excitation light will add to the green emission signal of the fluorophore to produce a green light of greater intensity.
The interference filter 103 can be a short pass filter that blocks all wavelengths beyond a certain point. The interference filter 103 can be a band pass filter that only allows a particular band of wavelengths to pass through the filter. In certain embodiments, the system 100 employs interference filters 102B and 102C that are band pass filters because, in certain embodiments, the excitation lights 101B and 101C have similar wavelengths. The use of two band pass filters can avoid frequency overlap between the two excitation lights, thereby resulting in two excitation lights with two distinct bands.
The use of the interference filter 103 can avoid the wavelength overlap between the excitation and emission wavelengths. In certain embodiments, the resulting light from the interference filters 103A-C can be transmitted through a focusing lens 104A-C. The focusing lens 104A-C directs the light into the respective optical fibers 105A-C. The optical fiber lines 105 may each comprise a single fiber or a bundle of fibers. The use of the fiber bundles can reduce the amount of dead space when the fibers are joined to the single fiber 108. In certain embodiments, each of the fiber optic lines 105 comprises a bundle of fibers that are bundled together to form a fiber bundle 106. The fiber bundle 106 can be connected to a single fiber optic line 108.
A measurement taken across the cross-section of fiber optic line 108 can show an uneven distribution of light. For example, some areas of the fiber may be darker than other areas of the fiber. In certain embodiments, a mode-mixing scrambler 109 is used to distribute the light such that the light is transmitted more uniformly across the optical fiber. The mode-mixing scrambler 109 can be configured to cause the light traveling down the fiber to lose the higher mode light. In certain embodiments, higher mode light is light propagating with large angles of incidence. In certain embodiments, higher mode light with an angle of incidence greater than the critical angle will pass out of the optical fiber. The mode-mixing scrambler 109 can be a length of fiber that is curved around a particular radius to create an optical fiber with a lower critical angle. Light transmitted through the mode-mixing scrambler 109 can result in a low-mode light that tends to travel straighter in the fiber. The single optical fiber 108 can be connected to another fiber optic line 110. The fiber optic line 110 may be a bundle of fibers or a single fiber.
In this embodiment, the light sensitive module (or detector system) comprises two detectors 112, 121. A portion of the light traveling through optical fiber 108 can be transmitted through the fiber optic line 110 and can be measured using the light sensitive module (or detector system) comprising a first detector 112. In certain embodiments, the signal produced from the first detector 112 can be amplified by an amplifier 113. The amplified signal can be converted from an analog signal to a digital signal by the analog-to-digital converter 114. In certain embodiments, the digital signal is transmitted to a data processing device 124 for storage and ratiometric processing. The data processing device 124 can be any data processing device of any type known in the art, for example, microprocessor, embedded processor, multiprocessor, general purpose computer, special purpose processor, computational devices, digital signal processor, microcontroller, programmable gate array or any combinations thereof. In certain embodiments, the single optical fiber 108 is connected to another fiber optic line 111. The fiber optic line 111 may be a bundle of fibers 115 or a single fiber.
A portion of the light traveling through the fiber optic line 108 can be transmitted through the fiber optic line 111 and into the glucose sensor 117. In certain embodiments, the cross-section of line 111 comprises a bundle of fibers 115A placed around a larger single fiber 115B before connecting to glucose sensor 117 at a first end 117A. The glucose sensor 117 can be an optical fiber. In certain embodiments, the glucose sensor has a mirror or reflective surface 117B at a second end of the glucose sensor 117. The fluorophore system of the glucose sensor can be embedded within, immobilized or otherwise associated with hydrogels that reside within holes or cavities 116 in the optical fiber. The fluorophore system can emit a fluorescent light when glucose is present and when the fluorophores are excited by an excitation light 101B, 101C. In certain embodiments, the fluorophore system comprises a dual exciter-single emitter dye (for example, a dye that produces a single emission peak in response to two different excitation lights). Of course other fluorophore systems may be used, including inter alia, single excitation-single emission, dual excitation-dual emission, and single excitation-dual emission).
The emission intensity can be directly related to the glucose concentration (that is, the greater the concentration of glucose, the stronger the intensity of light emitted by the fluorophore system). In certain embodiments, the emission intensity is inversely related to the glucose concentration (that is, the greater the concentration of glucose, the lower the intensity of light emitted by the fluorophore system). A portion of the excitation and emission wavelengths can be transmitted into the fiber optic line 118. The fiber optic line 118 may be a single fiber line, as shown in cross-section 119, or a bundle of optical fibers (not shown). The light transmitted through fiber optic line 118 can be filtered through an interference filter 120. The interference filter 120 can block the excitation lights generated from the light sources 101B and 101C.
The remaining light spectrum comprises emission wavelengths from the fluorophore reporters and the reference light from the light source 101A. In certain embodiments, the remaining light spectrum is measured using the light sensitive module (or detector system) comprising a second detector 121. The signal produced by the second detector 121 can be amplified by an amplifier 122. The amplified signal can be converted from an analog signal to a digital signal by an analog-to-digital converter 123. In certain embodiments, the resulting digital signal is transmitted to computer 124 for storage and ratiometric processing.
The optical glucose measurement system 100 can be configured to pulse light from the light sources 101. For example, the system 100 may transmit light from the reference light source 101A for one second, and then wait one second, and then transmit light from the first excitation light source 101B for one second, and then wait one second, and then transmit light from the second excitation light source 101C for one second and then wait one second before repeating this light pulsation pattern. In certain embodiments, the system 100 would continuously repeat such a light pulsation pattern until the system 100 was turned off. The pulse frequency and duration could vary greatly depending on the desired effect as will be appreciated by one skilled in the art.
The ambient light can affect the intensity of the emission wavelengths. In certain embodiments, the optical glucose measurement system 100 accounts for ambient light effects by taking a first measurement of the light intensity in the system 100 when one of the light sources 101 is on and then taking a second measurement of the light intensity in the system when all the light sources 101 are off. The ambient light effect can be eliminated by subtracting the second measurement from the first measurement.
The bending of the fiber optic lines affects the intensity of the emission wavelengths. The bending of the fiber can create light loss from the fiber optic line. In certain embodiments, the temperature changes affect the performance of the detectors and amplifiers of the system 100, thereby affecting the intensity of the emission wavelength that is detected. There can be factors that affect emission wavelength intensity that do not relate to changes in glucose concentration. To account for the fiber bending, the temperature changing, and other non-glucose related effects on emission wavelength intensity, the system 100 is configured, in certain embodiments, to employ ratiometric calculations to eliminate non-glucose related intensity changes.
The second detector 121 can be configured to measure emission wavelength emitted from the fluorophore system in the sensing cavities 116. In certain embodiments, the detector 121 measures the reference light generated from light source 101A. The fiber bending, the temperature changing, and other non-glucose related factors can affect the intensity of the reference light and the emission wavelength in the same way, thereby allowing ratiometric calculations to eliminate non-glucose related effects on light intensity. The ratiometric calculation employed can involve dividing the measured emission wavelength by the measured reference light, where both measurements are taken at the second detector 121. The ratio of the measured emission wavelength to the measured reference light can cross referenced with a pre-determined function that correlates this ratio to the amount of glucose present. In certain embodiments, the ratio of measured emission wavelength to measured reference light changes only if the glucose concentration changes.
The reference light emitted from light source 101A can be affected by various factors in the system 100, whereas, for example, the first excitation light emitted from light source 101B is unaffected. The system 100 can account for such disparate changes between the reference light and the excitation lights by periodically measuring these lights over time at the first detector 112. In certain embodiments, a ratio is produced that compares the periodic measurements with the first measurement of each light, for example, reference light at time equals zero seconds divided by reference light at time equals one second. A similar ratio can be created for the excitation lights. For example, if the reference light ratio does not equal one then a change occurred in the reference light that should be accounted for before determining the glucose concentration. For example, if a change to the reference light was detected at the first detector 112, then the reference light measured at the second detector 121 should be adjusted to account for this change. For example, if the reference light measurement at the first detector 112 increased then the reference light measured at the second detector 121 must be decreased. In certain embodiments, the decrease is determined by multiplying the measured reference light at the second detector 121 by the following, (reference light at time=0/reference light at time=1), where the reference light measurements were taken from the first detector 112. The same ratiometric calculations can be completed for the emission wavelengths detected at the second detector 121 except that the first and second excitation lights are measured instead of the reference light.
The emission signals and the reference signal can be affected by various factors such that the percent change in all the signals is essentially the same. In certain embodiments these changes can be corrected for by taking the ratio of the emission signal and the reference signal after they are adjusted for changes over time as previously described. Examples of such factors include but are not limited to fiber bending which can result in a loss of light from the fiber.
In certain embodiments, the glucose sensing chemistry is immobilized within the hydrogels in cavities 116. With reference to
With reference to
The hydrogels can be associated with a plurality of fluorophore systems. The fluorophore systems can comprise a quencher with a glucose receptor site. When there is no glucose present to bind with the glucose receptor, the quencher can prevent the fluorophore system from emitting light when the dye is excited by an excitation light. In certain embodiments, when there is glucose present to bind with the glucose receptor, the quencher allows the fluorophore system to emit light when the dye is excited by an excitation light.
The emission produced by the fluorophore system can vary with the pH of the solution (for example, blood), such that different excitation wavelengths (one exciting the acid form of the fluorophore and the other the base form of the fluorophore) produce different emissions signals. In preferred embodiments, the ratio of the emissions signal from the acid form of the fluorophore over the emission signal from the base form of the fluorophore is related to the pH level of the blood. An interference filter can be employed to ensure that the two excitation lights are exciting only one form (the acid form or the base form) of the fluorophore.
With reference to
In certain embodiments, light is transmitted from each of the light sources 201 through an optical module comprising a collimator lens 202, an interference filter 203, and/or a focusing lens 204. The resulting substantially collimated light can be transmitted through an interference filter 203 that blocks a portion of the spectrum of each light. The inference filter 203 can block the portion of spectrum that overlaps with the emission wavelengths generated from the glucose sensing fluorophore systems 208, which correspond to the hydrogels 116 as described above with reference to
The resulting light from the interference filter 203 can be transmitted through a focusing lens 204. The focusing lens 204 can be configured to direct the light into the fiber optic lines 205. The fiber optic lines 205 may each comprise a single fiber or a bundle of fibers. The use of fiber bundles can reduce the amount of dead space when the fibers are joined to the single fiber 206. In certain embodiments, each of the fiber optic lines 205 comprises a bundle of fibers that are bundled together to form a fiber bundle 206. The fiber bundle 206 can comprise a single optical fiber 210 surrounded by fiber optic lines 205. The fiber optic line 210 can comprise a bundle of fiber optic lines.
The fiber bundle 206 can be configured to connect to a first end of a glucose sensor 207. The glucose sensor 207 can comprise a single optical fiber 207A that further comprises a hydrogel 208 as described above in reference to
The excitation light can be configured to generate from the light sources 201B, 201C and the reference light generated from the light source 201A are transmitted into the glucose sensor. In certain embodiments, the excitation light excites the fluorophore systems when glucose is present. The excitation light, the reference light and the emission light can be reflected off the mirror or reflective surface 209 and into the fiber optic line 210. In certain embodiments, the excitation light, the reference light and the emission light is transmitted into the fiber optic line 210.
The light transmitted through optical fiber 210 can be transmitted through a collimator lens 211. In certain embodiments, the resulting light is substantially collimated, and is transmitted to a beam splitter 212. The beam splitter 212 can be configured to reflect substantially all emission light and substantially all reference light, while transmitting substantially all excitation light.
The beam splitter 212 can be an interference filter that can be designed to work at a substantially forty-five degree angle. In certain embodiments, the beam splitter 212 is a glass surface with a coating that will reflect light having a certain wavelength and allow all other light to pass through the beam splitter 212. The beam splitter can be positioned at a substantially forty-five degree angle relative the direction of the light traveling from the collimator lens 211. In certain embodiments, the beam splitter 212 reflects all of the emission light and a portion of the reference light. The beam splitter 212 can transmit or allow the excitation light and the remaining portion of the reference light to pass through the beam splitter 212. The reference light can have a spectral bandwidth. In certain embodiments, the beam splitter 212 divides the reference spectral band light at a wavelength near the point where the reference light experiences maximum amplitude in order to minimize intensity changes due to spectral shifts in the reference light.
In this embodiment, the light sensitive module (or detector system) comprises two detectors 215A, 215B. The emission light and the portion of reference light that can be reflected by the beam splitter 212 can be measured using the light sensitive module (or detector system) comprising a first detector 215A. In certain embodiments, the signal produced by detector 215A is amplified by amplifier 216A. The amplified signal can be converted from an analog to a digital signal by an analog-to-digital converter 217A. The digital signal can be transmitted to computer 218 for storage and ratiometric processing. In certain embodiments, the excitation light and the portion of the reference light that is transmitted through the beam splitter 212 is measured by a second detector 215B. The signal produced by detector 215B can be amplified by amplifier 216B. In certain embodiments, the amplified signal is converted from an analog to a digital signal by an analog-to-digital converter 217B. The digital signal is transmitted to computer 218 for storage and ratiometric processing.
The optical glucose measurement system 200 can determine the glucose concentration in the blood by taking the ratio of the emission light over the excitation light, wherein the emission light is measured at the first detector 215 and the excitation light is measured at the second detector 216. In certain embodiments, the ratio of the emission light to the excitation light is cross referenced with a pre-determined function that correlates this ratio to the glucose concentration in the blood. The ratio of the emission light to the excitation light is known as the Glucose Ratio. The glucose ratio can, in certain embodiments, be unaffected by changes in the light source intensity, the coupling efficiency of the light source into the optical fibers, bending of the optical fibers or the like. In certain embodiments, the ratio of emission light over excitation light changes only if the glucose concentration changes.
The detectors 215, 216 and the amplifiers 215A, 216A can be affected by various factors, such as temperature, that result in variances in the measured light intensity. These variances created by the two detectors 215, 216 and two amplifiers 215A, 216A can be eliminated or substantially eliminated by taking the ratio of the reference light measured at the first detector 215 and the reference light measured at the second detector 216. In certain embodiments, the foregoing ratio compares the differences between the first detector 215 system and the second detector system 216.
The optical glucose measurement system 200 can determine the ratio of the reference light measured at the first detector 215 and the reference light measured at the second detector 216 at time equals zero, and this ratio is used as a Reference Ratio to compare with measurements taken at subsequent periods. In certain embodiments, a difference between the reference ratio and subsequent ratios indicates that a change has occurred in one of the detectors systems. For example, the foregoing ratio equals to 1/1 at time equals zero, whereas the ratio equals to 1/10 at time equals one. In this example, the two ratios are not equal because the second detector 216 has measured a signal that is ten times the signal that was measured at time equals zero, therefore, to account for this disparity the inverse of the foregoing ratio at time equals one, specifically the ratio of 10/1, is multiplied against the Glucose Ratio.
With reference to
The fiber optic lines 205B, 205C can surround a fiber optic line 210, which is shown in
Similar to the embodiment described above with reference to
The light generated by the light source 201D can be transmitted through a collimator lens 202D. In certain embodiments, a focusing lens 204D focuses the resulting light from the collimator lens 202D into a optical fiber 210 which transmits the light through collimator lens 211. The light generated by the light source 201D can comprise two colors of different wavelengths. The two colors can be the same as the excitation light and the emission wavelength. For example, in a system where the excitation light is blue and the emission wavelength is green, then light generated by the light source 201D is a blue light comprising both blue and green light. In certain embodiments, the beam splitter 212 will reflect the green light while allowing the blue to pass through the lens. The reflected green light can be measured at detector 215A and the transmitted light is measured at detector 215B.
Ratiometric calculations can be performed by taking the ratio of the reflected light over the transmitted light at time equals zero, wherein this ratio is used as a reference ratio. In certain embodiments, the foregoing ratio is taken at subsequent times and compared to the reference ratio. Where subsequent ratios do not equal the reference ratio, the inverse of the subsequent ratio can be multiplied against the Glucose Ratio, as described above with reference to
The systems described above may be augmented, in certain embodiments, by substituting the beam splitter 212 as described above with a beam splitter that reflects s-polarized light towards the first detector 215A in the light sensitive module while allowing p-polarized light to pass through the beam splitter 212 and to the second detector 215B in the light sensitive module. In certain embodiments, an interference filter is placed before the first detector 212 that blocks all excitation light before transmitting the remaining light (emission light and reference light) to first detector 215A. An interference filter can be placed before the second detector 215B that blocks all emission light before transmitting the remaining light (excitation light and reference light) to the second detector 215B. The disadvantage of this system is that some of the emission and excitation signals are not being fully measured.
The systems described above, with reference to
The systems described above with reference to
With reference to
The emission light and the excitation lights can be transmitted from the glucose sensor into the fiber optic line 309, as described above with reference to
The microspectrometer can be the UV/VIS Microspectrometer Module manufactured by Boehringer Ingelheim. Any microspectrometer can be used. Alternatively, the microspectrometer could be substituted with other spectrometer, such as those manufactured by Ocean Optic Inc.
In certain embodiments described above, the ratiometric calculations require measurements of various light intensities. These measurements can be determined by measuring the peak amplitudes at a particular wavelength or wavelength band. These measurements can be determined by calculating the area under the curve between two particular wavelengths as for example with the output from a microspectrometer.
The use of a microspectrometer and/or spectrometer can allow the glucose measurement system 300 to be easily changed when different fluorophore systems are employed. For example, if the system 300 is manufactured with a fluorophore system that emits a green emission wavelength and if later research and development shows that a fluorophore system that emits a red emission wavelength is better at detecting glucose concentrations, then in such a situation one would only need to replace the glucose sensor and the software to perform the ratiometric calculations. In such an example, one would not need to change interference filters or beam splitters.
The systems described above with reference to
The systems described above with reference to
The first emission wavelength can be related to the concentration of acid in the blood. In certain embodiments, the second emission wavelength is related to the concentration of base in the blood. The ratio of intensities of the first emission light over the second emission light can be related to the pH level of the blood. As described above with reference to
The systems described above with reference to
With reference to
The systems described above with reference to
With reference to
The systems described above with reference to
The systems described above with reference to
With reference to all of the foregoing systems described above, in certain embodiments, the light transmitted from the light sources does not travel through an optical module comprising a collimator lens, an interference filter, and a focusing lens before being transmitted through the glucose sensor. Instead, as shown in
With reference to all of the foregoing systems described above, in certain embodiments, the interference filter may be replaced with other types of filters, for example, wratten filters.
The indicator system (also referred to herein as a fluorophore system) can comprise a fluorophore operably coupled to a quencher. In certain embodiments, the fluorophore system comprises a polymer matrix comprising a fluorophore susceptible to quenching by a viologen, a viologen quencher with quenching efficacy dependent on glucose concentration, and a glucose permeable polymer, wherein said matrix is in contact with blood in vivo. Preferably the fluorophore is a fluorescent organic dye, the quencher is a boronic acid functionalized viologen, and the matrix is a hydrogel.
Fluorophores
“Fluorophore” refers to a substance that when illuminated by light at a particular wavelength emits light at a longer wavelength; i.e. it fluoresces. Fluorophores include but are not limited to organic dyes, organometallic compounds, metal chelates, fluorescent conjugated polymers, quantum dots or nanoparticles and combinations of the above. Fluorophores may be discrete moieties or substituents attached to a polymer.
Fluorophores that may be used in preferred embodiments are capable of being excited by light of wavelength at or greater than about 400 nm, with a Stokes shift large enough that the excitation and emission wavelengths are separable by at least 10 nm. In some embodiments, the separation between the excitation and emission wavelengths may be equal to or greater than about 30 nm. These fluorophores are preferably susceptible to quenching by electron acceptor molecules, such as viologens, and are resistant to photo-bleaching. They are also preferably stable against photo-oxidation, hydrolysis and biodegradation.
In some embodiments, the fluorophore may be a discrete compound.
In some embodiments, the fluorophore may be a pendant group or a chain unit in a water-soluble or water-dispersible polymer having molecular weight of about 10,000 daltons or greater, forming a dye-polymer unit. In one embodiment, such dye-polymer unit may also be non-covalently associated with a water-insoluble polymer matrix M1 and is physically immobilized within the polymer matrix M1, wherein M1 is permeable to or in contact with analyte solution. In another embodiment, the dye on the dye-polymer unit may be negatively charged, and the dye-polymer unit may be immobilized as a complex with a cationic water-soluble polymer, wherein said complex is permeable to or in contact with the analyte solution. In one embodiment, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid. The polymeric dyes may be water-soluble, water-swellable or dispersible in water. In some embodiments, the polymeric dyes may also be cross-linked. In preferred embodiments, the dye has a negative charge.
In other embodiments, the dye molecule may be covalently bonded to the water-insoluble polymer matrix M1, wherein said M1 is permeable to or in contact with the analyte solution. The dye molecule bonded to M1 may form a structure M1-L1-Dye. L1 is a hydrolytically stable covalent linker that covalently connects the sensing moiety to the polymer or matrix. Examples of L1 include lower alkylene (e.g., C1-C8 alkylene), optionally terminated with or interrupted by one or more divalent connecting groups selected from sulfonamide (—SO2NH—), amide —(C═O)N—, ester —(C═O)—O—, ether —O—, sulfide —S—, sulfone (—SO2—), phenylene —C6H4—, urethane —NH(C═O)—O—, urea —NH(C═O)NH—, thiourea —NH(C═S)—NH—, amide —(C═O)NH—, amine —NR—(where R is defined as alkyl having 1 to 6 carbon atoms) and the like, or a combination thereof. In one embodiment, the dye is bonded to a polymer matrix through the sulfonamide functional groups.
In some embodiments, useful dyes include pyranine derivatives (e.g. hydroxypyrene trisulfonamide derivatives and the like), which have the following formula:
##STR00001##
wherein R1, R2, R3 are each —NHR4, R4 is —CH2CH2(—OCH2CH2—)nX1; wherein X1 is —OH, —OCH3COOH, —CONH2, —SO3H, —NH2, or OMe; and n is between about 70 and 10,000. In one embodiment, the dyes may be bonded to a polymer through the sulfonamide functional groups. In other embodiments, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid.
In some embodiments, the fluorescent dye may be 8-hydroxypyrene-1,3,6-trisulfonate (HPTS). The counterions can be H+ or any other cation. HPTS exhibits two excitation wavelengths at around 450 nm and around 405 nm, which correspond to the absorption wavelengths of the acid and its conjugate base. The shift in excitation wavelength is due to the pH-dependent ionization of the hydroxyl group on HPTS. As the pH increases, HPTS shows an increase in absorbance at about 450 nm, and a decrease in absorbance below about 420 nm. The pH-dependent shift in the absorption maximum enables dual-excitation ratiometric detection in the physiological range. This dye has a molecular weight of less than 500 daltons, so it will not stay within the polymer matrix, but it can be used with an anion exclusion membrane.
##STR00002##
In another embodiment, the fluorescent dye may be polymers of 8-acetoxy-pyrene-1,3,6-N,N′,N″-tris-(methacrylpropylamidosulfonamide) (acetoxy-HPTS-MA):
##STR00003##
It is noted that dyes such as acetoxy-HPTS-MA (above) having no anionic groups, may not give very strong glucose response when operably coupled to a viologen quencher, particularly a viologen quencher having only a single boronic acid moiety.
In another embodiment, the fluorescent dye may be 8-hydroxy-pyrene-1,3,6-N, N′,N″-tris-(carboxypropylsulfonamide) (HPTS-CO2):
##STR00004##
In another embodiment, the fluorescent dye may be 8-hydroxy-pyrene-1,3,6-N, N′,N″-tris-(methoxypolyethoxyethyl (˜125) sulfonamide) (HPTS-PEG):
##STR00005##
It is noted that dyes such as HPTS-PEG (above) having no anionic groups, may not provide a very strong glucose response when operably coupled to a viologen quencher, particularly a viologen quencher having only a single boronic acid moiety.
Representative dyes as discrete compounds are the tris adducts formed by reacting 8-acetoxypyrene-1,3,6-trisulfonylchloride (HPTS-Cl) with an amino acid, such as amino butyric acid. Hydroxypyrene trisulfonamide dyes bonded to a polymer and bearing one or more anionic groups are most preferred, such as copolymers of 8-hydroxypyrene-1-N-(methacrylamidopropylsulfonamido)-N′,N″-3,6-bis(carboxypropylsulfonamide) HPTS-CO2-MA with HEMA, PEGMA, and the like.
In another embodiment, the fluorescent dye may be HPTS-TriCys-MA:
##STR00006##
This dye may be used with a quencher comprising boronic acid, such as 3,3′-oBBV.
Of course, in some embodiments, substitutions other than Cys-MA on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. Either L or D stereoisomers of cysteine may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to HPTS-CysMA shown above, other counterions besides NBu4+ may be used, including positively charged metals, e.g., Na+. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc. functional groups.
Another suitable dye is HPTS-LysMA, which is pictured below as follows:
##STR00007##
Other examples include soluble copolymers of 8-acetoxypyrene-1,3,6-N,N′, N″-tris(methacrylamidopropylsulfonamide) with HEMA, PEGMA, or other hydrophilic comonomers. The phenolic substituent in the dye is protected during polymerization by a blocking group that can be removed by hydrolysis after completion of polymerization. Such suitable blocking groups, as for example, acetoxy, trifluoroacetoxy, and the like, are well known in the art.
Fluorescent dyes, including HPTS and its derivatives are known and many have been used in analyte detection. See e.g., U.S. Pat. Nos. 6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; and co-pending U.S. patent application Ser. Nos. 11/296,898, 11/671,880, 11/782,553, and 60/954,204; each of which is incorporated herein in its entirety by reference thereto.
The SNARF and SNAFL dyes from Molecular Probes may also be useful fluorophores in accordance with aspects of the present invention. The structures of SNARF-1 and SNAFL-1 are shown below.
##STR00008##
Additionally, a set of isomeric water-soluble fluorescent probes based on both the 6-aminoquinolinium and boronic acid moieties which show spectral shifts and intensity changes with pH, in a wavelength-ratiometric and colorimetric manner may be useful in accordance with some embodiments of the present invention (See e.g., Badugu, R. et al. 2005 Talanta 65 (3):762-768; and Badugu, R. et al. 2005 Bioorg. Med. Chem. 13 (1):113-119); incorporated herein in its entirety by reference.
Another example of a fluorescence dye that may be pH and saccharide sensitive is tetrakis(4-sulfophenyl)porphine (TSPP)—shown below. TSPP may not work optimally in blood, where the porphyrin ring may react with certain metal ions, like ferric, and become non-fluorescent.
##STR00009##
Additional examples of pH sensitive fluorescent indicators that may be useful for simultaneous determination of pH and glucose in the sensor of the present invention are described in US 2005/0233465 and US 2005/0090014; each of which is incorporated herein by reference in its entirety.
Analyte Binding Moieties—Quenchers
In accordance with broad aspects of the present invention, the analyte binding moiety provides the at least dual functionality of being able to bind analyte and being able to modulate the apparent concentration of the fluorophore (e.g., detected as a change in emission signal intensity) in a manner related to the amount of analyte binding. In preferred embodiments, the analyte binding moiety is associated with a quencher. “Quencher” refers to a compound that reduces the emission of a fluorophore when in its presence. Quencher (Q) is selected from a discrete compound, a reactive intermediate which is convertible to a second discrete compound or to a polymerizable compound or Q is a pendant group or chain unit in a polymer prepared from said reactive intermediate or polymerizable compound, which polymer is water-soluble or dispersible or is an insoluble polymer, said polymer is optionally crosslinked.
In one example, the moiety that provides glucose recognition in the embodiments is an aromatic boronic acid. The boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen). “Viologen” refers generally to compounds having the basic structure of a nitrogen containing conjugated N-substituted heterocyclic aromatic bis-onium salt, such as 2,2′-, 3,3′- or 4,4′-N,N′ bis-(benzyl) bipyridium dihalide (i.e., dichloride, bromide chloride), etc. Viologen also includes the substituted phenanthroline compounds. The boronic acid substituted quencher preferably has a pKa of between about 4 and 9, and reacts reversibly with glucose in aqueous media at a pH from about 6.8 to 7.8 to form boronate esters. The extent of reaction is related to glucose concentration in the medium. Formation of a boronate ester diminishes quenching of the fluorophore by the viologen resulting in an increase in fluorescence dependent on glucose concentration. A useful bis-onium salt is compatible with the analyte solution and capable of producing a detectable change in the fluorescent emission of the dye in the presence of the analyte to be detected.
Bis-onium salts in the embodiments of this invention are prepared from conjugated heterocyclic aromatic di-nitrogen compounds. The conjugated heterocyclic aromatic di-nitrogen compounds are selected from dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes, phenanthrolines, and diazafluorenes, wherein the nitrogen atoms are in a different aromatic ring and are able to form an onium salt. It is understood that all isomers of said conjugated heterocyclic aromatic di-nitrogen compounds in which both nitrogens can be substituted are useful in this invention. In one embodiment, the quencher may be one of the bis-onium salts derived from 3,3′-dipyridyl, 4,4′-dipyridyl and 4,7-phenanthroline.
In some embodiments, the viologen-boronic acid adduct may be a discrete compound having a molecular weight of about 400 daltons or greater. In other embodiments, it may also be a pendant group or a chain unit of a water-soluble or water-dispersible polymer with a molecular weight greater than about 10,000 daltons. In one embodiment, the quencher-polymer unit may be non-covalently associated with a polymer matrix and is physically immobilized therein. In yet another embodiment, the quencher-polymer unit may be immobilized as a complex with a negatively charge water-soluble polymer.
In other embodiments, the viologen-boronic acid moiety may be a pendant group or a chain unit in a crosslinked, hydrophilic polymer or hydrogel sufficiently permeable to the analyte (e.g., glucose) to allow equilibrium to be established.
In other embodiments, the quencher may be covalently bonded to a second water-insoluble polymer matrix M2, which can be represented by the structure M2-L2-Q. L2 is a linker selected from the group consisting of a lower alkylene (e.g., C1-C8 alkylene), sulfonamide, amide, quaternary ammonium, pyridinium, ester, ether, sulfide, sulfone, phenylene, urea, thiourea, urethane, amine, and a combination thereof. The quencher may be linked to M2 at one or two sites in some embodiments.
For the polymeric quencher precursors, multiple options are available for attaching the boronic acid moiety and a reactive group which may be a polymerizable group or a coupling group to two different nitrogens in the heteroaromatic centrally located group. These are:
Preferred embodiments comprise two boronic acid moieties and one polymerizable group or coupling group wherein the aromatic group is a benzyl substituent bonded to the nitrogen and the boronic acid groups are attached to the benzyl ring and may be in the ortho-meta or para-positions.
In some embodiments, the boronic acid substituted viologen as a discrete compound useful for in vitro sensing may be represented by one of the following formulas:
##STR00010##
where n=1-3, X is halogen, and Y1 and Y2 are independently selected from phenyl boronic acid (o- m- or p-isomers) and naphthyl boronic acid. In other embodiments, the quencher may comprise a boronic acid group as a substituent on the heterocyclic ring of a viologen.
A specific example used with TSPP is m-BBV:
##STR00011##
The quencher precursors suitable for making sensors may be selected from the following:
##STR00012## ##STR00013##
The quencher precursor 3,3′-oBBV may be used with HPTS-LysMA or HPTS-CysMA to make hydrogels in accordance with preferred aspects of the invention.
Preferred quenchers are prepared from precursors comprising viologens derived from 3,3′-dipyridyl substituted on the nitrogens with benzylboronic acid groups and at other positions on the dipyridyl rings with a polymerizable group or a coupling group. Representative viologens include:
##STR00014##
where L is L1 or L2 and is a linking group
Z is a reactive group; and
R′ is —B(OH)2 in the ortho-meta- or para-positions on the benzyl ring and R″ is H—; or optionally R″ is a coupling group as is defined herein or a substituent specifically used to modify the acidity of the boronic acid such as fluoro- or methoxy-.
L is a divalent moiety that covalently connects the sensing moiety to a reactive group that is used to bind the viologen to a polymer or matrix. Examples of L include those which are each independently selected from a direct bond or, a lower alkylene having 1 to 8 carbon atoms, optionally terminated with or interrupted by one or more divalent connecting groups selected from sulfonamide (—SO2NH—), amide —(C═O)N—, ester —(C═O)—O—, ether —O—, sulfide —S—, sulfone (—SO2—), phenylene —C6H4—, urethane —NH(C═O)—O—, urea —NH(C═O)NH—, thiourea —NH(C═S)—NH—, amide —(C═O)NH—, amine —NR— (where R is defined as alkyl having 1 to 6 carbon atoms) and the like.
Z is either a polymerizable ethylenically unsaturated group selected from but not limited to methacrylamido-, acrylamido-, methacryloyl-, acryloyl-, or styryl- or optionally Z is a reactive functional group, capable of forming a covalent bond with a polymer or matrix. Such groups include but are not limited to —Br, —OH, —SH, —CO2H, and —NH2.
Boronic acid substituted polyviologens are another class of preferred quenchers. The term polyviologen includes: a discrete compound comprised of two or more viologens covalently bonded together by a linking group, a polymer comprised of viologen repeat units in the chain, a polymer with viologen groups pendant to the chain, a dendrimer comprised of viologen units, preferably including viologen terminal groups, an oligomer comprised of viologen units, preferably including viologen endgroups, and combinations thereof. Polymers in which mono-viologen groups form a minor component are not included. The preferred quenchers are water soluble or dispersible polymers, or crosslinked, hydrophilic polymers or hydrogels sufficiently permeable to glucose to function as part of a sensor. Alternatively the polyviologen boronic acid may be directly bonded to an inert substrate.
A polyviologen quencher as a polymer comprised of viologen repeat units has the formula:
##STR00015##
In another embodiment, the polyviologen boronic acid adducts are formed by covalently linking two or more viologen/boronic acid intermediates. The bridging group is typically a small divalent radical bonded to one nitrogen in each viologen, or to a carbon in the aromatic ring of each viologen, or one bond may be to a ring carbon in one viologen and to a nitrogen in the other. Two or more boronic acid groups are attached to the polyviologen. Optionally, the polyviologen boronic acid adduct is substituted with a polymerizable group or coupling group attached directly to the viologen or to the bridging group. Preferably the polyviologen moiety includes only one such group. Preferably, the bridging group is selected to enhance cooperative binding of the boronic acids to glucose.
The coupling moiety is a linking group as defined previously with the proviso that the linking group is optionally further substituted with a boronic acid, a polymerizable group, an additional coupling group, or is a segment in a polymer chain in which the viologen is a chain unit, a pendant group, or any combination thereof.
Glucose-binding quenchers are known and many have been used in analyte detection. See e.g., U.S. Pat. Nos. 6,653,141, 6,627,177 and co-pending U.S. patent application Ser. Nos. 11/296,898, 11/671,880, 11/782,553, 60/915,372 and 60/949,145; each of which is incorporated herein in its entirety by reference thereto.
Immobilizing Means—e.g., Hydrogels
For embodiments that are to be used in vitro, the sensing components are used as individual (discrete) components. The analyte, dye and quencher are mixed together in liquid solution, the change in fluorescence intensity is measured, and the components are discarded. Polymeric matrices which can be used to trap the components to prevent leaching need not be present.
For in vivo applications, the sensor is used in a moving stream of physiological fluid which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor assembly. Thus, for use in vivo, the sensing components are preferably part of an organic polymer sensing assembly. Soluble dyes and quenchers can be confined by a semi-permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using as sensing moieties soluble molecules that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selective semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific molecular weight cutoff between the two so that the sensing moieties are quantitatively retained.
Preferably the sensing moieties are immobilized in an insoluble polymer matrix, which is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest.
The function of the polymer matrix is to hold together and immobilize the fluorophore and quencher moieties while at the same time allowing contact with the analyte, and binding of the analyte to the boronic acid. To achieve this effect, the matrix must be insoluble in the medium, and in close association with it by establishing a high surface area interface between matrix and analyte solution. For example, an ultra-thin film or microporous support matrix is used. Alternatively, the matrix is swellable in the analyte solution, e.g. a hydrogel matrix is used for aqueous systems. In some instances, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. In all cases, the matrix must not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels are established in the art. All useful matrices are defined as being analyte permeable.
Hydrogel polymers are used in some embodiments. The term, hydrogel, as used herein refers to a polymer that swells substantially, but does not dissolve in water. Such hydrogels may be linear, branched, or network polymers, or polyelectrolyte complexes, with the proviso that they contain no soluble or leachable fractions. Typically, hydrogel networks are prepared by a crosslinking step, which is performed on water-soluble polymers so that they swell but do not dissolve in aqueous media. Alternatively, the hydrogel polymers are prepared by copolymerizing a mixture of hydrophilic and crosslinking monomers to obtain a water swellable network polymer. Such polymers are formed either by addition or condensation polymerization, or by combination process. In these cases, the sensing moieties are incorporated into the polymer by copolymerization using monomeric derivatives in combination with network-forming monomers. Alternatively, reactive moieties are coupled to an already prepared matrix using a post polymerization reaction. Said sensing moieties are units in the polymer chain or pendant groups attached to the chain.
The hydrogels useful in this invention are also monolithic polymers, such as a single network to which both dye and quencher are covalently bonded, or multi-component hydrogels. Multi-component hydrogels include interpenetrating networks, polyelectrolyte complexes, and various other blends of two or more polymers to obtain a water swellable composite, which includes dispersions of a second polymer in a hydrogel matrix and alternating microlayer assemblies.
Monolithic hydrogels are typically formed by free radical copolymerization of a mixture of hydrophilic monomers, including but not limited to HEMA, PEGMA, methacrylic acid, hydroxyethyl acrylate, N-vinyl pyrrolidone, acrylamide, N,N′-dimethyl acrylamide, and the like; ionic monomers include methacryloylaminopropyl trimethylammonium chloride, diallyl dimethyl ammonium. chloride, vinyl benzyl trimethyl ammonium chloride, sodium sulfopropyl methacrylate, and the like; crosslinkers include ethylene dimethacrylate, PEGDMA, trimethylolpropane triacrylate, and the like. The ratios of monomers are chosen to optimize network properties including permeability, swelling index, and gel strength using principles well established in the art. In one embodiment, the dye moiety is derived from an ethylenically unsaturated derivative of a dye molecule, such as 8-acetoxypyrene-1,3,6-N,N′,N″-tris(methacrylamidopropylsulfonamide), the quencher moiety is derived from an ethylenically unsaturated viologen such as 4-N-(benzyl-3-boronic acid)-4′-N′-(benzyl-4-ethenyl)-dipyridinium dihalide (m-SBBV) and the matrix is made from HEMA and PEGDMA. The concentration of dye is chosen to optimize emission intensity. The ratio of quencher to dye is adjusted to provide sufficient quenching to produce the desired measurable signal.
In some embodiments, a monolithic hydrogel is formed by a condensation polymerization. For example, acetoxy pyrene trisulfonyl chloride is reacted with an excess of PEG diamine to obtain a tris-(amino PEG) adduct dissolved in the unreacted diamine. A solution of excess trimesoyl chloride and an acid acceptor is reacted with 4-N-(benzyl-3-boronic acid)-4′-N′-(2 hydroxyethyl) bipyridinium dihalide to obtain an acid chloride functional ester of the viologen. The two reactive mixtures are brought into contact with each other and allowed to react to form the hydrogel, e.g. by casting a thin film of one mixture and dipping it into the other.
In other embodiments, multi-component hydrogels wherein the dye is incorporated in one component and the quencher in another are preferred for making the sensor of this invention. Further, these systems are optionally molecularly imprinted to enhance interaction between components and to provide selectivity for glucose over other polyhydroxy analytes. Preferably, the multicomponent system is an interpenetrating polymer network (IPN) or a semi-interpenetrating polymer network (semi-IPN).
The IPN polymers are typically made by sequential polymerization. First, a network comprising the quencher is formed. The network is then swollen with a mixture of monomers including the dye monomer and a second polymerization is carried out to obtain the IPN hydrogel.
The semi-IPN hydrogel is formed by dissolving a soluble polymer containing dye moieties in a mixture of monomers including a quencher monomer and through complex formation with the fluorophore. In some embodiments, the sensing moieties are immobilized by an insoluble polymer matrix which is freely permeable to polyhydroxyl compounds. Additional details on hydrogel systems have been disclosed in US Patent Publications Nos. US2004/0028612, and 2006/0083688 which are hereby incorporated by reference in their entireties.
The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest. The function of the polymer matrix is to hold together and immobilize the fluorescent dye and quencher moieties while at the same time allowing contact with the analytes (e.g., polyhydroxyl compounds, H+ and OH−), and binding of the polyhydroxyl compounds to the boronic acid. Therefore, the matrix is insoluble in the medium and in close association with it by establishing a high surface area interface between matrix and analyte solution. The matrix also does not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. In one embodiment, an ultra-thin film or microporous support matrix may be used. In another embodiment, the matrix that is swellable in the analyte solution (e.g. a hydrogel matrix) can be used for aqueous systems. In some embodiments, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels have been established in the prior art.
In one preferred embodiment, the boronic acid substituted viologen may be covalently bonded to a fluorescent dye. The adduct may be a polymerizable compound or a unit in a polymer. One such adduct for example may be prepared by first forming an unsymmetrical viologen from 4,4′-dipyridyl by attaching a benzyl-3-boronic acid group to one nitrogen and an aminoethyl group to the other nitrogen atom. The viologen is condensed sequentially first with 8-acetoxy-pyrene-1,3,6-trisulfonyl chloride in a 1:1 mole ratio followed by reaction with excess PEG diamine to obtain a prepolymer mixture. An acid acceptor is included in both steps to scavange the byproduct acid. The prepolymer mixture is crosslinked by reaction with a polyisocyanate to obtain a hydrogel. The product is treated with base to remove the acetoxy blocking group. Incomplete reaction products and unreacted starting materials are leached out of the hydrogel by exhaustive extraction with deionized water before further use. The product is responsive to glucose when used as the sensing component as described herein.
Alternatively, such adducts are ethylenically unsaturated monomer derivatives. For example, dimethyl bis-bromomethyl benzene boronate is reacted with excess 4,4′-dipyridyl to form a half viologen adduct. After removing the excess dipyridyl, the adduct is further reacted with an excess of bromoethylamine hydrochloride to form the bis-viologen adduct. This adduct is coupled to a pyranine dye by reaction with the 8-acetoxypyrene-tris sulfonyl chloride in a 1:1 mole ratio in the presence of an acid acceptor followed by reaction with excess aminopropylmethacrylamide. Finally, any residual amino groups may be reacted with methacryloyl chloride. After purification, the dye/viologen monomer may be copolymerized with HEMA and PEGDMA to obtain a hydrogel.
Immobilizing means, e.g., hydrogels, are known and many have been used in analyte detection. See e.g., U.S. Pat. Nos. 6,653,141, 6,627,177 and co-pending U.S. patent application Ser. Nos. 11/296,898, 11/671,880, and 11/782,553; each of which is incorporated herein in its entirety by reference thereto.
To a solution of HPTS-CysMA (1×10−5 M in pH 7.4 PBS) was added increasing amounts of 3,3′-oBBV (30 mM in MeOH) and the fluorescence emission measured after each addition.
HPTS-CysMA (1×10-5 M) and 3,3′-oBBV (3×10-3 M) were titrated with a stock solution of glucose (31250 mg/dL) in pH 7.4 PBS and the fluorescence emission measured after each addition of glucose The relative change upon addition of glucose is given in
HPTS-CysMA (2 mg), 3,3′-oBBV (15 mg), N/N′-dimethylacrylamide (400 mg), N,N′-methylenebisacrylamide (8 mg), HCl (10 μL of 1 M solution), and VA-044 (1 mg) were dissolved in water and diluted to 1 mL in a volumetric flask. The solution was freeze-pump-thawed (3×), injected into a mold containing a 0.005″ polyimide spacer and polymerized at 55° C. for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and was tested in a flow cell configuration with increasing amounts of glucose (0, 50, 100, 200, 400 mg/dL). The relative fluorescence change upon addition of glucose is given in
In certain embodiments, the examples, systems and methods set forth in the foregoing disclosure may be embodied in part or in whole in software that is running on a computing device. The functionality provided for in the components and modules of the computing device may comprise one or more components and/or modules. For example, the computing device may comprise multiple central processing units (CPUs) and a mass storage device, such as may be implemented in an array of servers.
In general, the word “module,” as used herein (except where it is used in connection with the optical and light sensitive modules described above), refers to logic embodied in hardware or firmware, or to a collection of software instructions, possibly having entry and exit points, written in a programming language, such as, for example, Java, C or C++. A software module may be compiled and linked into an executable program, installed in a dynamic link library, or may be written in an interpreted programming language such as, for example, BASIC, Perl, Lua, or Python. It will be appreciated that software modules may be callable from other modules or from themselves, and/or may be invoked in response to detected events or interrupts. Software instructions may be embedded in firmware, such as an EPROM. It will be further appreciated that hardware modules may be comprised of connected logic units, such as gates and flip-flops, and/or may be comprised of programmable units, such as programmable gate arrays or processors. The modules described herein are preferably implemented as software modules, but may be represented in hardware or firmware. Generally, the modules described herein refer to logical modules that may be combined with other modules or divided into sub-modules despite their physical organization or storage.
In certain embodiments, the computing device communicates with one or more databases that store information, including credit data and/or non-credit data. This database or databases may be implemented using a relational database, such as Sybase, Oracle, CodeBase and Microsoft® SQL Server as well as other types of databases such as, for example, a flat file database, an entity-relationship database, and object-oriented database, and/or a record-based database.
In certain embodiments, the computing device is IBM, Macintosh, or Linux/Unix compatible. In certain embodiments, the computing device comprises a server, a laptop computer, a cell phone, a personal digital assistant, a kiosk, or an audio player, for example. In certain embodiment, the computing device includes one or more CPUs, which may each include microprocessors. The computing device may further include one or more memory devices, such as random access memory (RAM) for temporary storage of information and read only memory (ROM) for permanent storage of information, and one or more mass storage devices, such as hard drives, diskettes, or optical media storage devices. In certain embodiments, the modules of the computing are in communication via a standards based bus system, such as bus systems using Peripheral Component Interconnect (PCI), Microchannel, SCSI, Industrial Standard Architecture (ISA) and Extended ISA (EISA) architectures, for example. In certain embodiments, components of the computing device communicate via a network, such as a local area network that may be secured.
The computing is generally controlled and coordinated by operating system software, such as the Unix, VxWorks, Windows 95, Windows 98, Windows NT, Windows 2000, Windows XP, Windows Vista, Linux, SunOS, Solaris, PalmOS, Blackberry OS, or other compatible operating systems or real-time operating systems. In other embodiments, the computing device may be controlled by a proprietary operating system. Conventional operating systems control and schedule computer processes for execution, perform memory management, provide file system, networking, and I/O services, and provide a user interface, such as a graphical user interface (“GUI”), among other things.
The computing device may include one or more commonly available input/output (I/O) devices and interfaces, such as a keyboard, mouse, touchpad, microphone, and printer. Thus, in certain embodiments the computing device may be controlled using the keyboard and mouse input devices, while in another embodiment the user may provide voice commands to the computing device via a microphone. In certain embodiments, the I/O devices and interfaces include one or more display device, such as a monitor, that allows the visual presentation of data to a user. More particularly, a display device provides for the presentation of GUIs, application software data, and multimedia presentations, for example. The computing device may also include one or more multimedia devices, such as speakers, video cards, graphics accelerators, and microphones, for example.
In certain embodiments, the I/O devices and interfaces provide a communication interface to various external devices. For example, the computing device may be configured to communicate with one or more networks, such as any combination of one or more LANs, WANs, a virtual private network (VPN), or the Internet, for example, via a wired, wireless, or combination of wired and wireless, communication links. The network communicates with various computing devices and/or other electronic devices via wired or wireless communication links.
Although the foregoing invention has been described in terms of certain embodiments and examples, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Moreover, the described embodiments have been presented by way of example only, and are not intended to limit the scope of the inventions. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. Accordingly, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Thus, the present invention is not intended to be limited by the example or preferred embodiments. The accompanying claims provide exemplary claims and their equivalents are intended to cover forms or modifications as would fall within the scope and spirit of the inventions.
Wessling, Ritchie A., Kolehmainen, Donald J., Markle, David R.
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 1120700, | |||
| 1334901, | |||
| 2018792, | |||
| 2094224, | |||
| 2112244, | |||
| 2274551, | |||
| 2496151, | |||
| 2812524, | |||
| 3011293, | |||
| 3302219, | |||
| 3488098, | |||
| 3659586, | |||
| 3685059, | |||
| 3795239, | |||
| 3827089, | |||
| 3865548, | |||
| 3874010, | |||
| 3884225, | |||
| 3895403, | |||
| 3905888, | |||
| 3909504, | |||
| 3924281, | |||
| 3930580, | Oct 19 1973 | Medical Products Corporation | Sterilizable, peelable pouch or tray assembly |
| 3996345, | Aug 12 1974 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| 4003707, | Feb 28 1975 | Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. | Method and arrangement for measuring the concentration of gases |
| 4041932, | Feb 06 1975 | Method for monitoring blood gas tension and pH from outside the body | |
| 4094578, | Feb 19 1976 | CSELT - Centro Studi e Laboratori Telecomunicazioni S.p.A. | Optical equalizer for signal-transmission system using multimode light guides |
| 4118485, | Mar 20 1975 | Aminkemi Aktiebolag | Non-thrombogenic medical article and a method for its preparation |
| 4180879, | Aug 04 1978 | Body positioner | |
| 4197853, | Jul 26 1977 | MEDTRONIC MINIMED, INC | PO2 /PCO2 sensor |
| 4200110, | Nov 28 1977 | United States of America | Fiber optic pH probe |
| 4240438, | Oct 02 1978 | Wisconsin Alumni Research Foundation | Method for monitoring blood glucose levels and elements |
| 4245645, | Sep 28 1977 | Self-locking cerebral electrical probe | |
| 4269605, | Jun 28 1978 | W R GRACE & CO -CONN | Method and kit for separation of glycoproteins |
| 4306562, | Dec 01 1978 | Cook, Inc. | Tear apart cannula |
| 4307933, | Feb 20 1980 | Hughes Missile Systems Company | Optical fiber launch coupler |
| 4308254, | Sep 19 1978 | Institut Merieux | Material able to fix reversibly biologial macromolecules, its preparation and its application |
| 4344438, | Aug 02 1978 | The United States of America as represented by the Department of Health, | Optical sensor of plasma constituents |
| 4345606, | Dec 13 1977 | LITTLEFORD,ELIZABETH H | Split sleeve introducers for pacemaker electrodes and the like |
| 4358851, | Feb 28 1980 | Xerox Corporation | Fiber optic laser device and light emitter utilizing the device |
| 4361918, | Jun 22 1978 | Devices and method for handling a person on a base | |
| 4371374, | Nov 17 1980 | The Rockefeller University; ROCKEFELLER UNIVERSITY THE, | Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine |
| 4459712, | Jun 11 1981 | Hospital bed | |
| 4465335, | |||
| 4469357, | Oct 09 1973 | AEROFIT PRODUCTS, INC | Composite coupling |
| 4474431, | Dec 20 1978 | STC plc | Optical fibre directional coupler |
| 4476870, | Mar 30 1982 | The United States of America as represented by the Department of Health | Fiber optic PO2 probe |
| 4490867, | Dec 21 1982 | Lycksele NYA Platprodukter AB | Bed rocking mechanism |
| 4495293, | Feb 24 1983 | Abbott Laboratories | Fluorometric assay |
| 4502169, | Jul 27 1981 | Apparatus for turning a person confined to bed | |
| 4528616, | Mar 28 1983 | AG COMMUNICATION SYSTEMS CORPORATION, 2500 W UTOPIA RD , PHOENIX, AZ 85027, A DE CORP | Printed wiring board enclosure |
| 4548907, | Sep 14 1983 | FISHER SCIENTIFIC COMPANY A CORP OF DE | Fluorescent fluid determination method and apparatus |
| 4557900, | Sep 28 1982 | Terumo Cardiovascular Systems Corporation | Optical sensor with beads |
| 4560248, | Aug 14 1981 | Imperial Chemical Industries, PLC | Fibre optic sensor with bonded dye |
| 4568444, | Apr 30 1984 | Kuraray Co., Ltd. | Chemical substance measuring apparatus |
| 4579641, | Jun 30 1984 | Terumo Kabushiki Kaisha | pH Measurement device |
| 4600310, | Mar 30 1981 | Imperial Chemical Industries PLC | Optical fibre sensor |
| 4621049, | Nov 19 1984 | Miles Laboratories, Inc. | Enzymatic high range glucose test |
| 4629451, | Sep 23 1985 | VICTORY YSI INCORPORATED | Stereotaxic array plug |
| 4636144, | Jul 06 1982 | Fujisawa Pharmaceutical Co., Ltd. | Micro-feed pump for an artificial pancreas |
| 4649271, | Jan 25 1984 | TAKAOKA ELECTRIC MFG CO , LTD | Fiber-optic acceleration sensor with photoluminescent material |
| 4650472, | Aug 30 1985 | Cook, Incorporated | Apparatus and method for effecting percutaneous catheterization of a blood vessel using a small gauge introducer needle |
| 4654031, | Apr 15 1985 | DESERET MEDICAL, INC , A CORP OF DE | Flash chamber |
| 4654127, | Apr 11 1984 | SenTech Medical Corporation | Self-calibrating single-use sensing device for clinical chemistry and method of use |
| 4659817, | Mar 24 1980 | The Children's Medical Center Corporation | Reporter compounds containing boron |
| 4675925, | Apr 03 1986 | Device for manipulating bedridden patients | |
| 4684538, | Feb 21 1986 | Loctite Corporation | Polysiloxane urethane compounds and adhesive compositions, and method of making and using the same |
| 4689308, | May 01 1986 | HOSPIRA, INC | Article for preparing a chemical sensor for use |
| 4703756, | May 06 1986 | Regents of the University of California, The | Complete glucose monitoring system with an implantable, telemetered sensor module |
| 4707056, | Dec 21 1984 | Carl-Zeiss-Stiftung | Optical arrangement having a concave mirror or concave grating |
| 4710623, | Feb 27 1986 | Eli Lilly and Company | Optical fiber catheter with fiber-contained reactive element |
| 4727730, | Jul 10 1986 | Medex, Inc. | Integrated optic system for monitoring blood pressure |
| 4737153, | Feb 07 1986 | TOYO CLOTH CO , LTD , 1754 TARUI, SENNAN-SHI, OSAKA-FU, JAPAN; JAPAN U-PICA CO , LTD , 1-1, 2-CHOME UCHISAIWAICHO, CHIYODA-KU, TOKYO, JAPAN | Reinforced therapeutic tube |
| 4744618, | May 03 1982 | Siemens Aktiengesellschaft | Optical device for use as a multiplexer or demultiplexer in accordance with the diffraction grating principle |
| 4746751, | May 07 1987 | Baxter Travenol Laboratories, Inc. | Silicone reactive/fluorescent silane dye compositions |
| 4750795, | Jun 13 1985 | The Board of Trustees of the Leland Stanford Junior University | Optical fiber coupler |
| 4751918, | Oct 15 1985 | Anti-bedsore bed having alternatively driven rollers to displace user | |
| 4754538, | Nov 15 1983 | Raychem Corporation | Annular tube-like driver |
| 4755173, | Feb 25 1986 | MEDTRONIC MINIMED, INC | Soft cannula subcutaneous injection set |
| 4776047, | May 07 1985 | Med Bed Technologies, Inc. | Multiple function invalid bed arrangement |
| 4785814, | Aug 11 1987 | Cordis Corporation | Optical probe for measuring pH and oxygen in blood and employing a composite membrane |
| 4792689, | Nov 12 1985 | The United States of America as represented by the Department of Health | Method for obtaining a ratio measurement for correcting common path variations in intensity in fiber optic sensors |
| 4794619, | Dec 05 1986 | Conax Buffalo Technologies LLC | Optical fiber temperature sensor |
| 4796633, | Jun 25 1985 | Baxter International Inc | Method and apparatus for in vitro calibration of oxygen saturation monitor |
| 4798738, | Oct 10 1986 | Terumo Cardiovascular Systems Corporation | Micro sensor |
| 4801187, | Apr 30 1986 | Bankers Trust Company | Liquid light tube end cap assembly |
| 4803049, | Dec 12 1984 | REGENTS OF THE UNIVERSITY OF CALIFORNIA THE | pH-sensitive optrode |
| 4810655, | Jul 03 1985 | HOSPIRA, INC | Method for measuring oxygen concentration |
| 4816130, | Jul 02 1987 | Becton, Dickinson and Company | Blood electrolyte sensors including crosslinked polyetherurethane membranes |
| 4820636, | Feb 21 1985 | GENETICS INTERNATIONAL, INC | Electrochemical assay for cis-diols |
| 4821738, | Nov 19 1987 | Vital Signs, Inc | Arterial blood gas syringe |
| 4822127, | Jun 16 1986 | MEDTRONIC MINIMED, INC | Multi-channel optical transmission system |
| 4833091, | Feb 06 1987 | MEDTRONIC MINIMED, INC | Sensor system |
| 4838269, | Mar 24 1988 | Boston Scientific Scimed, Inc | Manifold for angioplasty balloon catheter |
| 4844841, | Jun 13 1986 | Pyrenexulfonic acids useful in fluorescent lipid probes | |
| 4846543, | May 02 1984 | Kaptron, Inc. | Star coupler for optical fibers |
| 4851195, | Aug 17 1987 | MEDTRONIC MINIMED, INC | Carbon dioxide sensor |
| 4854321, | Jun 18 1986 | Medex, Inc. | Integrated optic system for monitoring blood gases |
| 4861728, | Jul 24 1987 | Becton, Dickinson and Company | Immunoassay of glycosylated hemoglobin using a labeled boron reagent |
| 4872226, | Jun 06 1988 | ROBERT LONARDO | Means for positioning bedfast patients |
| 4872759, | Jul 08 1987 | Siemens Aktiengesellschaft | Sensor for gases or ions |
| 4886338, | Oct 10 1986 | Terumo Cardiovascular Systems Corporation | Optical fiber event sensor |
| 4889407, | Dec 02 1988 | MEDTRONIC MINIMED, INC | Optical waveguide sensor and method of making same |
| 4903707, | Apr 22 1988 | CAMINO NEUROCARE, INC | Ventricular catheter assembly |
| 4906232, | Mar 01 1988 | Abbott Laboratories | Intravascular delivery device |
| 4923273, | Oct 13 1987 | Texas A&M University System | Method for producing reflective taps in optical fibers and applications thereof |
| 4927222, | Jun 16 1986 | MEDTRONIC MINIMED, INC | Dual optical fiber device |
| 4937901, | Nov 04 1988 | Apparatus for turning a patient from a supine to a prone position and vice-versa | |
| 4939801, | Dec 22 1988 | Patient transporting and turning gurney | |
| 4941308, | Jul 25 1988 | Abbott Laboratories | Method of packaging for a sterilizable calibratable medical device |
| 4943364, | Jun 21 1985 | BECTON DICKINSON CRITICAL CARE SYSTEMS PTE LTD | Fiber optic CO2 sensor |
| 4946038, | Dec 20 1989 | EATON FORMS CORPORATION, A CORP OF OH | Medicine container and cover therefor |
| 4955862, | May 22 1989 | STRYKER EUROPEAN HOLDINGS III, LLC | Catheter and catheter/guide wire device |
| 4960412, | Apr 15 1988 | Merit Medical Systems, Inc | Catheter introducing system |
| 4966597, | Nov 04 1988 | Sherwood Services AG | Thermometric cardiac tissue ablation electrode with ultra-sensitive temperature detection |
| 5000901, | Jul 25 1988 | HOSPIRA, INC | Fiber-optic physiological probes |
| 5005576, | Apr 09 1988 | Koninklijke Philips Electronics N V | Optical probe |
| 5007704, | Oct 28 1983 | Edwards Lifesciences Corporation | Oximeter |
| 5012809, | Oct 10 1986 | Fiber optic catheter system with fluorometric sensor and integral flexure compensation | |
| 5018225, | Dec 23 1988 | Italpres S.n.c. di Frengni Bruno & C. | Appparatus for preventing and healing bedsores in long-term inpatients |
| 5030420, | Dec 23 1982 | University of Virginia Alumni Patents Foundation | Apparatus for oxygen determination |
| 5047208, | Feb 23 1989 | Medtronic, Inc. | Blood gas monitoring sensors |
| 5047627, | May 18 1990 | HOSPIRA, INC | Configuration fiber-optic blood gas sensor bundle and method of making |
| 5054497, | Feb 21 1990 | Biomedical Monitors and Implants, Inc. | Cranial sensor attaching device and method for its use |
| 5068931, | Jun 21 1991 | ARY LIFT, INC , A CORP OF NC | Apparatus for lifting and turning a patient confined to a bed |
| 5069674, | Nov 23 1988 | Medical Engineering and Development Institute, Inc.; MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC | Flexible, kink-resistant catheter |
| 5082112, | Feb 05 1991 | United States Surgical Corporation | Package for endoscopic ligating instrument |
| 5093266, | Feb 06 1987 | MEDTRONIC MINIMED, INC | Sensor system |
| 5098618, | Mar 14 1990 | Surface modification of plastic substrates | |
| 5104388, | May 08 1990 | FBK International Corporation | Membrane splittable tubing |
| 5108502, | Mar 16 1990 | Hewlett-Packard Company | Boronic acid dyes |
| 5109452, | Jul 16 1990 | Puritan-Bennett Corporation | Electrical-optical hybrid connector |
| 5114676, | Aug 04 1988 | AVL AG | Optical sensor for determining at least one parameter in a liquid or gaseous sample |
| 5119463, | Apr 09 1991 | HOSPIRA, INC | Compound optical probe employing single optical waveguide |
| 5132432, | Sep 22 1989 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
| 5137833, | Sep 21 1989 | MEDTRONIC MINIMED, INC | Method for detecting polyhydroxyl compounds |
| 5141497, | Jun 06 1989 | BECTON, DICKINSON AND COMPANY, A CORP OF NJ | Apparatus and method for an introducer |
| 5156962, | Nov 28 1986 | Takeda Chemical Industries, Ltd. | Process for producing carboxylic acid esters using carboxyesterase and an anhydride in organic solvent |
| 5162130, | Dec 17 1986 | Light activated coloration of dental restorations | |
| 5166990, | Aug 10 1990 | PURITAN-BENNETT CORPORATION A CORP OF DELAWARE | Multiple optical fiber event sensor and method of manufacture |
| 5167715, | Mar 04 1991 | General Electric Company | Apparatus and method for impregnating superconductor windings |
| 5168587, | May 18 1992 | MEDTRONIC MINIMED, INC | Patient positioning device |
| 5175016, | Mar 20 1990 | Terumo Cardiovascular Systems Corporation | Method for making gas sensing element |
| 5176882, | Dec 06 1990 | Pelikan Technologies, Inc | Dual fiberoptic cell for multiple serum measurements |
| 5178267, | Dec 20 1990 | ABBOTT LABORATORIES, ABBOTT PARK, LAKE, IL A CORP OF IL | Packaging system for a sterilizable calbratable medical device |
| 5180376, | May 01 1990 | CATHCO, INC A CORPORATION OF MD | Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters |
| 5182353, | Aug 16 1989 | Puritan-Bennett Corporation | Method for bonding an analyte-sensitive dye compound to an addition-cure silicone |
| 5185263, | Oct 23 1987 | AVL Medical Instruments AG | Method for calibration of a measurement apparatus |
| 5188803, | Dec 01 1988 | Abbott Laboratories | Device for preparing a medical sensor for use |
| 5217691, | Nov 19 1984 | Miles Inc. | Nonenzymatic glucose test |
| 5230031, | May 22 1992 | MEDTRONIC MINIMED, INC | Barrier for a connector |
| 5246109, | May 22 1992 | MEDTRONIC MINIMED, INC | Package for an active medical device |
| 5246441, | Sep 08 1989 | Linvatec Corporation | Bioabsorbable tack for joining bodily tissue |
| 5257338, | May 22 1992 | MEDTRONIC MINIMED, INC | Device for transmitting and returning light and apparatus and method of manufacture |
| 5262037, | May 22 1992 | MEDTRONIC MINIMED, INC | Electrochemical sensor |
| 5279596, | Jul 27 1990 | Cordis Corporation | Intravascular catheter with kink resistant tip |
| 5280130, | May 22 1992 | MEDTRONIC MINIMED, INC | Assembly of a tube and a part and apparatus and method of manufacture |
| 5280548, | Mar 11 1993 | OHMEDA SINGAPORE PTE LTD | Emission based fiber optic sensors for pH and carbon dioxide analysis |
| 5286294, | Apr 24 1991 | Gen Gen Corporation | Vacuum coating apparatus |
| 5290266, | Aug 14 1992 | General Electric Company | Flexible coating for magnetic resonance imaging compatible invasive devices |
| 5302731, | Jul 13 1992 | Becton, Dickinson and Company | Fluorescent pH indicators |
| 5305740, | Sep 12 1991 | HEALTH AND HUMAN SERVICES, THE UNITED STATES OF AMERICAS, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | Sealing means for endotracheal tubes |
| 5310471, | May 22 1992 | MEDTRONIC MINIMED, INC | Method for manufacturing an electro chemical sensor |
| 5312344, | Feb 25 1991 | Arterial perfusion cannula for extracorporeal circulation and other uses | |
| 5322513, | Jan 22 1992 | Advanced Cardiovascular Systems, INC | Easy-to-handle, self-guiding catheter stripper |
| 5330718, | Aug 16 1989 | Puritan-Bennett Corporation | Sensor element and method for making the same |
| 5334157, | Sep 09 1993 | Gesco International, Inc. | Catheter introducer |
| 5354448, | May 22 1992 | MEDTRONIC MINIMED, INC | Electrochemical sensor |
| 5357732, | May 22 1992 | MEDTRONIC MINIMED, INC | Method for assembling package for an active medical device |
| 5361758, | Jun 09 1988 | Nellcor Puritan Bennett LLC | Method and device for measuring concentration levels of blood constituents non-invasively |
| 5380304, | Aug 07 1991 | Cook Medical Technologies LLC | Flexible, kink-resistant, introducer sheath and method of manufacture |
| 5389217, | Apr 28 1994 | MEDTRONIC MINIMED, INC | Measurement of bladder oxygen |
| 5391250, | Mar 15 1994 | MEDTRONIC MINIMED, INC | Method of fabricating thin film sensors |
| 5409469, | Nov 04 1993 | Medtronic, Inc. | Introducer system having kink resistant splittable sheath |
| 5485408, | Sep 09 1992 | SMITHS MEDICAL ASD, INC | Pump simulation apparatus |
| 5503770, | Nov 07 1993 | Research Development Corporation of Japan | Fluorescent compound suitable for use in the detection of saccharides |
| 5511408, | Jul 30 1992 | Horiba, LTD | Automatic calibrating apparatus for laboratory ion concentration meter |
| 5511547, | Feb 16 1994 | MEDTRONIC MINIMED, INC | Solid state sensors |
| 5512246, | Sep 21 1989 | MEDTRONIC MINIMED, INC | Method and means for detecting polyhydroxyl compounds |
| 5514710, | Jan 11 1994 | Molecular Probes, Inc.; MOLECULAR PROBES INC | Photocleavable derivatives of hydroxyprenesulfonic acids |
| 5522803, | Mar 09 1993 | UNOMEDICAL A S | Infusion set for an intermittent or continuous administration of a therapeutical substance |
| 5536783, | Jun 10 1993 | Optical Sensors Incorporated | Fluorescent polymers useful in conjunction with optical PH sensors |
| 5545179, | Jul 21 1995 | Ethicon Endo-Surgery, Inc. | Endoscopic access assembly |
| 5558714, | Nov 16 1989 | N. E. Chemcat Corporation | Tank and work-holder apparatus for liquid coating for honeycomb structure |
| 5569186, | Apr 25 1994 | MEDTRONIC MINIMED, INC | Closed loop infusion pump system with removable glucose sensor |
| 5578818, | May 10 1995 | GE Healthcare Bio-Sciences Corp | LED point scanning system |
| 5596988, | Jun 30 1993 | MEDTRONIC MINIMED, INC | Multi-parameter sensor apparatus |
| 5605152, | Jul 18 1994 | MEDTRONIC MINIMED, INC | Optical glucose sensor |
| 5618587, | Jun 30 1993 | MEDTRONIC MINIMED, INC | Vacuum rig apparatus |
| 5622259, | Jun 07 1995 | MEDTRONIC MINIMED, INC | Reduction of discoloration in plastic materials |
| 5634911, | May 19 1995 | General Surgical Innovations, Inc | Screw-type skin seal with inflatable membrane |
| 5643212, | Jan 30 1989 | HOSPIRA, INC | Infusion pump management system for suggesting an adapted course of therapy |
| 5658264, | Nov 10 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | High performance spiral-wound catheter |
| 5665065, | May 26 1995 | MEDTRONIC MINIMED, INC | Medication infusion device with blood glucose data input |
| 5669920, | Jul 09 1993 | Advanced Cardiovascular Systems, INC | Atherectomy catheter |
| 5676784, | Mar 15 1995 | HOSPIRA, INC | Method of fabricating a heater coil for a catheter used to monitor cardiac output |
| 5700253, | Aug 07 1991 | Cook Medical Technologies LLC | Flexible, kink-resistant, introducer sheath and method of manufacture |
| 5702373, | Aug 31 1995 | Target Therapeutics, Inc | Composite super-elastic alloy braid reinforced catheter |
| 5747666, | Mar 26 1997 | Point-of-care analyzer module | |
| 5755704, | Oct 29 1996 | Medtronic, Inc. | Thinwall guide catheter |
| 5763238, | Dec 28 1995 | Research Development Corporation of Japan | Boronic acid compound having a binaphthyl group |
| 5797876, | Nov 27 1995 | TherOx, Inc.; Wayne State University; TherOx, Inc | High pressure perfusion device |
| 5800420, | Nov 04 1994 | Elan Corporation, PLC | Analyte-controlled liquid delivery device and analyte monitor |
| 5807375, | Nov 04 1994 | Elan Corporation, PLC | Analyte-controlled liquid delivery device and analyte monitor |
| 5810985, | Sep 14 1992 | Purdue Research Foundation | Electrophoretically mediated chemical analysis |
| 5827242, | Jun 21 1996 | Medtronic Ave, Inc | Reinforced catheter body and method for its fabrication |
| 5891100, | Jan 25 1995 | GMS Gesellschaft fur Medizinische Sondentechnik mbH | Securing device for brain scan probes |
| 5891114, | Sep 30 1997 | Target Therapeutics, Inc | Soft-tip high performance braided catheter |
| 5922612, | May 02 1994 | Novartis Corporation | Optical sensor system for determining pH values and ionic strengths |
| 5925021, | Mar 09 1994 | Becton, Dickinson and Company | Medication delivery device with a microprocessor and characteristic monitor |
| 5947940, | Jun 23 1997 | Catheter reinforced to prevent luminal collapse and tensile failure thereof | |
| 5951929, | Dec 12 1995 | Jomed GmbH | Method for forming a catheter having overlapping welds |
| 5954643, | Jun 09 1997 | MEDTRONIC MINIMED, INC | Insertion set for a transcutaneous sensor |
| 5954651, | Aug 18 1993 | Boston Scientific Scimed, Inc | Catheter having a high tensile strength braid wire constraint |
| 6002954, | Nov 22 1995 | Lawrence Livermore National Security, LLC | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
| 6011984, | Nov 22 1995 | MEDTRONIC MINIMED, INC | Detection of biological molecules using chemical amplification and optical sensors |
| 6017328, | Jan 21 1993 | ING U S CAPITAL, LLC | Device for subcutaneous medication delivery |
| 6019736, | Nov 06 1995 | Francisco J., Avellanet | Guidewire for catheter |
| 6117290, | Sep 26 1997 | Pepex Biomedical, LLC | System and method for measuring a bioanalyte such as lactate |
| 6152933, | Nov 12 1997 | STEREOTAXIS, INC | Intracranial bolt and method of placing and using an intracranial bolt to position a medical device |
| 6156010, | Jun 17 1997 | INJECTIMED, INC | Method and apparatus for introducing an intravenous catheter |
| 6175752, | Apr 30 1998 | Abbott Diabetes Care Inc | Analyte monitoring device and methods of use |
| 6186982, | May 05 1998 | Alkermes Pharma Ireland Limited | Subcutaneous drug delivery device with improved filling system |
| 6187130, | May 26 1999 | Boston Scientific Scimed, Inc | Method of creating a tip on a catheter |
| 6200301, | Sep 05 1997 | Pulsion Medical Systems AG | Process and devices for determining the instant of injection and the duration of injection in thermodilution measurements |
| 6246992, | Oct 16 1996 | Health Hero Network | Multiple patient monitoring system for proactive health management |
| 6248067, | Feb 05 1999 | MEDTRONIC MINIMED, INC | Analyte sensor and holter-type monitor system and method of using the same |
| 6248093, | Oct 29 1998 | MEDTRONIC MINIMED, INC | Compact pump drive system |
| 6254829, | Oct 03 1997 | Roche Diagnostics Corporation | Optochemical sensor |
| 6273874, | Aug 18 1999 | Becton, Dickinson and Company | Protected peelable U-wing introducer |
| 6304766, | Aug 26 1998 | Sensors for Medicine and Science | Optical-based sensing devices, especially for in-situ sensing in humans |
| 6319540, | Nov 22 1995 | MiniMed Inc. | Detection of biological molecules using chemical amplification and optical sensors |
| 6355021, | Jul 14 1998 | UNOMEDICAL A S | Medical puncturing device |
| 6363273, | Dec 22 1999 | INTEGRA LIFESCIENCES CORPORATION | Introducer element and method of using same |
| 6370406, | Nov 20 1995 | Cirrex Systems, LLC | Method and apparatus for analyzing a test material by inducing and detecting light-matter interactions |
| 6375627, | Mar 02 2000 | Sanofi-Aventis Deutschland GmbH | Physiological fluid extraction with rapid analysis |
| 6379301, | Jan 10 1997 | Health Hero Network | Diabetes management system and method for controlling blood glucose |
| 6387672, | Dec 04 2000 | Baxter International Inc; BAXTER HEALTHCARE SA | Photo-induced electron transfer fluorescent sensor molecules |
| 6464849, | Oct 07 1999 | PEPEX BIOMEDICAL, L L C | Sensor for measuring a bioanalyte such as lactate |
| 6544212, | Jul 31 2001 | Roche Diabetes Care, Inc | Diabetes management system |
| 6558351, | Jun 03 1999 | MEDTRONIC MINIMED, INC | Closed loop system for controlling insulin infusion |
| 6584335, | Aug 09 1997 | Roche Diagnostics GmbH | Analytical device for in vivo analysis in the body of a patient |
| 6585665, | Oct 02 1998 | MEDTRONIC MINIMED, INC | Probe |
| 6591876, | Nov 05 1999 | Medtronic MiniMed, Inc. | Needle safe transfer guard |
| 6595919, | May 13 1998 | Lifescan IP Holdings, LLC | Device for signal processing for measurement of physiological analytes |
| 6602702, | Jul 16 1999 | TEXAS SYSTEM, UNIVERSITY OF, THE | Detection system based on an analyte reactive particle |
| 6623490, | Oct 02 1998 | MEDTRONIC MINIMED, INC | Cranial bolt |
| 6627177, | Dec 05 2000 | CALIFORNIA, UNIVERSITY OF THE REGENTS OF THE | Polyhydroxyl-substituted organic molecule sensing optical in vivo method utilizing a boronic acid adduct and the device thereof |
| 6641533, | Aug 18 1998 | Medtronic MiniMed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
| 6653141, | Dec 05 2000 | Regents of the University of California, The | Polyhydroxyl-substituted organic molecule sensing method and device |
| 6663595, | Dec 23 1999 | TELEFLEX MEDICAL INCORPORATED | Peelable PTFE sheaths and methods for manufacture of same |
| 6682938, | Sep 15 1999 | Lawrence Livermore National Security LLC | Glucose sensing molecules having selected fluorescent properties |
| 6702972, | Jun 09 1998 | MEDTRONIC MINIMED, INC | Method of making a kink-resistant catheter |
| 6711423, | Aug 26 1998 | Senseonics, Incorporated | Optical-based sensing devices |
| 6736797, | Jun 19 1998 | UNOMEDICAL A S | Subcutaneous infusion set |
| 6749587, | Feb 22 2002 | INSULET CORPORATION | Modular infusion device and method |
| 6766183, | Nov 22 1995 | Lawrence Livermore National Security, LLC | Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers |
| 6794195, | Aug 04 2000 | Senseonics, Incorporated | Detection of analytes in aqueous environments |
| 6800451, | Jan 05 2001 | SENSORS FOR MEDICINE AND SCIENCE, INC | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| 6801420, | Apr 19 2001 | MEDTRONIC MINIMED, INC | Selective potting for controlled failure and electronic devices employing the same |
| 6804544, | Nov 22 1995 | MiniMed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
| 6858403, | Sep 30 1998 | M-BIOTECH,INC | Polymer matrix containing catalase co-immobilized with analytic enzyme that generates hydrogen peroxide |
| 6934572, | Oct 20 1997 | Alfred E. Mann Foundation for Scientific Research | Implantable enzyme-based monitoring system having improved longevity due to improved exterior surfaces |
| 7003336, | Feb 10 2000 | MEDTRONIC MINIMED, INC | Analyte sensor method of making the same |
| 7029444, | Feb 23 2000 | Medtronic MiniMed, Inc. | Real time self-adjusting calibration algorithm |
| 7033322, | May 15 2000 | Implantable sensor | |
| 7064103, | Jan 04 2002 | Becton, Dickinson and Company | Binding protein as biosensors |
| 7066909, | Apr 23 1997 | Roche Diabetes Care, Inc | Propelling device for a piston in a container containing a liquid medicament |
| 7096053, | Oct 02 2001 | University of Southern California | Internal biochemical sensing device |
| 7137964, | Sep 08 2000 | INSULET CORPORATION | Devices, systems and methods for patient infusion |
| 7181260, | Nov 14 2003 | Apparatus and method for measuring myocardial oxygen consumption | |
| 7226414, | Oct 09 2002 | BIO TEX, INC | Method and apparatus for analyte sensing |
| 7229450, | Feb 11 2003 | Pacesetter, Inc.; Pacesetter, Inc | Kink resistant introducer with mapping capabilities |
| 7276028, | Jun 10 2003 | LIFECARE A S | Sensor in vivo measurement of osmotic changes |
| 7276029, | Aug 01 2003 | DEXCOM, INC | System and methods for processing analyte sensor data |
| 7277740, | Mar 15 2003 | Roche Diabetes Care, Inc | Analysis system for reagent-free determination of the concentration of an analyte in living tissue |
| 7277745, | Aug 07 1998 | Infinite Biomedical Technologies, LLC | Implantable myocardial ischemia detection, indication and action technology |
| 7303549, | Apr 23 2002 | INSULET CORPORATION | Transcutaneous fluid delivery system |
| 7316909, | Jan 04 2002 | Becton, Dickinson and Company | Binding protein as biosensors |
| 7317111, | Sep 23 2002 | CONRAD, MICHAEL J ; ARIES ASSOCIATES, INC | Green and orange fluorescent labels and their uses |
| 7353055, | Jun 18 2003 | COMPACT IMAGING, INC | Non-invasive analysis system |
| 7358094, | May 01 2003 | Baxter International Inc; BAXTER HEALTHCARE SA | Sensor system for saccharides |
| 7367942, | Feb 02 2006 | PALCO LABS, INC | Method and apparatus for testing blood glucose in a reversible infusion line |
| 7381938, | Sep 05 1995 | Canon Kabushiki Kaisha | Photoelectric converter and x-ray image pick-up device |
| 7390462, | Dec 17 2002 | MARYLAND BALTIMORE COUNTY, UNIVERSITY OF | Ratiometric fluorescent pH sensor for non-invasive monitoring |
| 7399277, | Dec 27 2001 | MEDTRONIC MINIMED, INC | System for monitoring physiological characteristics |
| 7417164, | Jul 25 2006 | MEDTRONIC MINIMED, INC | Fluorescent dyes for use in glucose sensing |
| 7442186, | Feb 28 2002 | SMITHS MEDICAL ASD, INC | Syringe pump control systems using a light sensor |
| 7446091, | May 05 2000 | Novo Nordisk A S | Methods and preparations for curing clinically ill patients |
| 7458938, | Sep 24 2002 | Mayo Foundation For Medical Education & Research | Peripherally inserted central catheter with continuous central venous oximetry and proximal high flow port |
| 7470420, | Dec 05 2000 | The Regents of the University of California | Optical determination of glucose utilizing boronic acid adducts |
| 7499746, | Jan 30 2004 | DJO GLOBAL SWITZERLAND SÀRL | Automated adaptive muscle stimulation method and apparatus |
| 7559894, | Sep 18 2003 | New Paradigm Concepts, LLC | Multiparameter whole blood monitor and method |
| 7602310, | Oct 08 1998 | Medtronic MiniMed, Inc. | Telemetered characteristic monitor system and method of using the same |
| 7604593, | May 16 2000 | Lifescan IP Holdings, LLC | Methods for measuring analyte in a subject and/or compensating for incomplete reaction involving detection of the analyte |
| 7615007, | Oct 04 2006 | DEXCOM, INC | Analyte sensor |
| 7625372, | Feb 23 2005 | Covidien LP | Methods and apparatus for coagulating and/or constricting hollow anatomical structures |
| 7647237, | Apr 29 1998 | MiniMed, Inc. | Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like |
| 7661301, | Feb 05 2004 | OXFORD MEDICAL DIAGNOSTICS LIMITED | Fluid analyser systems |
| 7699807, | Nov 10 2003 | SMITHS MEDICAL ASD, INC | Device and method for insertion of a cannula of an infusion device |
| 7722913, | Oct 20 1997 | Alfred E. Mann Foundation for Scientific Research | Implantable enzyme-based monitoring system having improved longevity due to improved exterior surfaces |
| 7727148, | Jul 27 2004 | Medtronic MiniMed, Inc. | Sensing system with auxiliary display |
| 7751863, | Feb 06 2007 | MEDTRONIC MINIMED, INC | Optical determination of ph and glucose |
| 7767846, | Jul 25 2006 | MEDTRONIC MINIMED, INC | Fluorescent dyes for use in glucose sensing |
| 7775975, | Oct 04 2006 | DEXCOM, INC | Analyte sensor |
| 7785313, | Apr 25 2007 | Medtronic MiniMed, Inc. | Closed loop/semi-closed loop therapy modification system |
| 7787923, | Nov 26 2003 | Becton, Dickinson and Company | Fiber optic device for sensing analytes and method of making same |
| 7806886, | Jun 03 1999 | MEDTRONIC MINIMED, INC | Apparatus and method for controlling insulin infusion with state variable feedback |
| 7807210, | Oct 31 2000 | Advanced Cardiovascular Systems, INC | Hemocompatible polymers on hydrophobic porous polymers |
| 7819843, | Aug 18 1998 | Medtronic MiniMed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
| 7824918, | Aug 06 2007 | MEDTRONIC MINIMED, INC | HPTS-Mono and BIS Cys-Ma polymerizable fluorescent dyes for use in analyte sensors |
| 7825086, | Dec 04 2001 | The Curators of the University of Missouri | Acyclovir-peptide analogs |
| 7828764, | Aug 23 2006 | Medtronic MiniMed, Inc.; MEDTRONIC MINIMED, INC | Systems and methods allowing for reservoir filling and infusion medium delivery |
| 7829341, | Jul 11 2007 | MEDTRONIC MINIMED, INC | Polyviologen boronic acid quenchers for use in analyte sensors |
| 7879010, | Apr 06 2001 | Roche Diabetes Care, Inc | Infusion set |
| 7879024, | Jun 26 2003 | ST JUDE MEDICAL, ATRIAL FIBRILLATION DIVISION, INC | Splittable cannula having radiopaque marker |
| 7881780, | Jan 18 2005 | BRAINGATE, INC | Biological interface system with thresholded configuration |
| 7888754, | Dec 28 2007 | Yamaha Corporation | MEMS transducer |
| 7890295, | Feb 23 2000 | MEDTRONIC MINIMED, INC | Real time self-adjusting calibration algorithm |
| 7892206, | Oct 29 1998 | Medtronic MiniMed, Inc. | Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump |
| 7892748, | Dec 16 2003 | MEDTRONIC MINIMED, INC | Reagent for detecting an analyte |
| 7901354, | Mar 04 1997 | DexCom, Inc. | Low oxygen in vivo analyte sensor |
| 7901394, | Jul 24 2002 | Medtronic MiniMed, Inc. | Physiological monitoring device for controlling a medication infusion device |
| 7939664, | May 01 2007 | MEDTRONIC MINIMED, INC | Pyridinium boronic acid quenchers for use in analyte sensors |
| 7942844, | Apr 28 2006 | MEDTRONIC MINIMED, INC | Remote monitoring for networked fluid infusion systems |
| 7946985, | Dec 29 2006 | MEDTRONIC MINIMED, INC | Method and system for providing sensor redundancy |
| 7955305, | May 06 2005 | MEDTRONIC MINIMED, INC | Needle inserter and method for infusion device |
| 7963954, | Apr 30 2007 | MEDTRONIC MINIMED, INC | Automated filling systems and methods |
| 7977112, | Jun 20 2003 | Roche Diabetes Care, Inc | System and method for determining an abused sensor during analyte measurement |
| 7979259, | Jan 10 1997 | Health Hero Network, Inc. | Diabetes care management system |
| 7981058, | Mar 12 2004 | TRUSTEES OF DARTMOUTH COLLEGE, THE | Intelligent wearable monitor systems and methods |
| 7985330, | Dec 30 2005 | MEDTRONIC MINIMED | Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy |
| 8024201, | Nov 17 1992 | Health Hero Network, Inc.; HEALTH HERO NETOWRK, INC | Method and apparatus for remote health monitoring and providing health related information |
| 8075499, | May 18 2007 | SMART MONITOR CORP | Abnormal motion detector and monitor |
| 8088097, | Nov 21 2007 | MEDTRONIC MINIMED, INC | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
| 8100852, | Nov 29 2006 | Medtronic MiniMed, Inc. | Methods and apparatuses for detecting medical device acceleration, temperature, and humidity conditions |
| 8110251, | Feb 06 2007 | MEDTRONIC MINIMED, INC | Method for polymerizing a monomer solution within a cavity to generate a smooth polymer surface |
| 8114268, | Dec 30 2005 | MEDTRONIC MINIMED, INC | Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy |
| 8114269, | Dec 30 2005 | MEDTRONIC MINIMED, INC | System and method for determining the point of hydration and proper time to apply potential to a glucose sensor |
| 8137314, | Aug 23 2006 | MEDTRONIC MINIMED, INC | Infusion medium delivery device and method with compressible or curved reservoir or conduit |
| 8178676, | May 01 2007 | MEDTRONIC MINIMED, INC | Pyridinium boronic acid quenchers for use in analyte sensors |
| 8181849, | Dec 30 2008 | MEDTRONIC MINIMED, INC | Color detection system for detecting reservoir presence and content in device |
| 8182462, | Sep 13 2005 | Medtronic MiniMed, Inc. | Modular external infusion device |
| 8192395, | Apr 08 2010 | Medtronic MiniMed, Inc. | System for providing blood glucose measurements to an infusion device |
| 8195265, | Aug 22 2003 | DexCom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| 8202250, | Aug 23 2006 | Medtronic MiniMed, Inc. | Infusion pumps and methods and delivery devices and methods with same |
| 8202731, | Aug 06 2007 | MEDTRONIC MINIMED, INC | HPTS-mono and bis Cys-MA polymerizable fluorescent dyes for use in analyte sensors |
| 8207859, | Apr 28 2008 | Medtronic MiniMed, Inc. | Automobile physiological monitoring system and method for using the same |
| 8226615, | Aug 23 2006 | Medtronic MiniMed, Inc. | Infusion medium delivery system, device and method with needle inserter and needle inserter device and method |
| 8257259, | Dec 09 2003 | DexCom, Inc. | Signal processing for continuous analyte sensor |
| 8263170, | Jul 30 2001 | Advanced Cardiovascular Systems, Inc. | Methods for immobilizing anti-thrombogenic material onto a medical device or into a coating thereon |
| 8267921, | Jul 20 2007 | Roche Diabetes Care, Inc | Manually operable portable infusion device |
| 8275437, | Aug 01 2003 | DEXCOM, INC | Transcutaneous analyte sensor |
| 8277415, | Aug 23 2006 | MEDTRONIC MINIMED, INC | Infusion medium delivery device and method with drive device for driving plunger in reservoir |
| 8283517, | Sep 12 2007 | Probiodrug AG | Transgenic mouse models of Aβ overexpression |
| 8287453, | Dec 05 2003 | DEXCOM, INC | Analyte sensor |
| 8292849, | Feb 05 1997 | Medtronic MiniMed, Inc. | Insertion device for an insertion set and method of using the same |
| 8298172, | Apr 13 2005 | Novo Nordisk A S | Medical skin mountable device and system |
| 8303572, | Oct 29 1998 | Medtronic MiniMed, Inc. | Medication reservoir |
| 8305580, | Dec 23 2003 | Precisense A/S | Fluorometers |
| 8308679, | Dec 30 2009 | Medtronic MiniMed, Inc. | Alignment systems and methods |
| 8313433, | Aug 06 2004 | MEDTRONIC MINIMED, INC | Medical data management system and process |
| 8318443, | Dec 16 2003 | Medtronic MiniMed, Inc. | Reagent for detecting an analyte |
| 8323250, | Apr 30 2007 | Medtronic MiniMed, Inc.; MEDTRONIC MINIMED, INC | Adhesive patch systems and methods |
| 8338138, | Jan 28 2004 | Johns Hopkins University, The | Methods for making and using molecular switches involving circular permutation |
| 8343092, | Mar 21 2005 | Abbott Diabetes Care Inc. | Method and system for providing integrated medication infusion and analyte monitoring system |
| 8352011, | Sep 08 2004 | Medtronic MiniMed, Inc. | Blood contacting sensor |
| 8353829, | Apr 30 1998 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| 8376968, | May 15 2009 | LEUNG, CHAK SENG | Method and system for quantifying an intention of movement of a user |
| 8394022, | Oct 30 2007 | SENSILE MEDICAL AG | Selectively permeable coated membrane |
| 8467843, | Nov 04 2009 | MEDTRONIC MINIMED, INC | Optical sensor configuration for ratiometric correction of blood glucose measurement |
| 8473222, | Mar 11 2010 | MEDTRONIC MINIMED, INC | Measurement devices and methods for measuring analyte concentration incorporating temperature and pH correction |
| 8498682, | Feb 06 2007 | MEDTRONIC MINIMED, INC | Optical determination of pH and glucose |
| 8509867, | Nov 12 2002 | CERCACOR LABORATORIES, INC | Non-invasive measurement of analytes |
| 8512245, | Apr 17 2008 | MEDTRONIC MINIMED, INC | Sensor for percutaneous intravascular deployment without an indwelling cannula |
| 8535262, | Nov 21 2007 | MEDTRONIC MINIMED, INC | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
| 8600681, | May 14 2007 | ABBOTT DIABETES CARE, INC | Method and apparatus for providing data processing and control in a medical communication system |
| 8658795, | May 01 2007 | MEDTRONIC MINIMED, INC | Pyridinium boronic acid quenchers for use in analyte sensors |
| 8668645, | Jan 02 2001 | Abbott Diabetes Care Inc | Analyte monitoring device and methods of use |
| 8700115, | Nov 04 2009 | MEDTRONIC MINIMED, INC | Optical sensor configuration for ratiometric correction of glucose measurement |
| 8715589, | Sep 30 2009 | MEDTRONIC MINIMED, INC | Sensors with thromboresistant coating |
| 8738107, | May 10 2007 | MEDTRONIC MINIMED, INC | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
| 8772047, | May 22 2007 | Becton, Dickinson and Company | Dyes having ratiometric fluorescence response for detecting metabolites |
| 8838195, | Feb 06 2007 | MEDTRONIC MINIMED, INC | Optical systems and methods for ratiometric measurement of blood glucose concentration |
| 8886273, | Oct 04 2006 | DEXCOM, INC | Analyte sensor |
| 8897868, | Sep 14 2007 | MEDTRONIC MONITORING, INC | Medical device automatic start-up upon contact to patient tissue |
| 8914090, | Sep 27 2006 | The University of Connecticut | Implantable biosensor and methods of use thereof |
| 8920344, | Apr 10 2006 | DIZZYCURE GMBH | Mobile balancing prosthesis |
| 8940544, | Feb 08 2010 | MEDTRONIC MINIMED, INC | Antioxidant protection of a chemical sensor |
| 20010016682, | |||
| 20020018843, | |||
| 20020026108, | |||
| 20020107178, | |||
| 20020128546, | |||
| 20020193672, | |||
| 20030013974, | |||
| 20030028089, | |||
| 20030065254, | |||
| 20030100821, | |||
| 20030171666, | |||
| 20030232383, | |||
| 20040028612, | |||
| 20040072358, | |||
| 20040087842, | |||
| 20040136924, | |||
| 20040219535, | |||
| 20040243018, | |||
| 20040260158, | |||
| 20040260162, | |||
| 20040267203, | |||
| 20050054975, | |||
| 20050090014, | |||
| 20050113658, | |||
| 20050118726, | |||
| 20050123935, | |||
| 20050130249, | |||
| 20050193860, | |||
| 20050233465, | |||
| 20050240086, | |||
| 20050241959, | |||
| 20050266038, | |||
| 20050267326, | |||
| 20050282225, | |||
| 20050283204, | |||
| 20060083688, | |||
| 20060084854, | |||
| 20060088722, | |||
| 20060105174, | |||
| 20060173252, | |||
| 20060189863, | |||
| 20060189979, | |||
| 20060195042, | |||
| 20060287600, | |||
| 20070020181, | |||
| 20070038155, | |||
| 20070060872, | |||
| 20070100356, | |||
| 20070123775, | |||
| 20070123819, | |||
| 20070136825, | |||
| 20070156079, | |||
| 20070175828, | |||
| 20070179437, | |||
| 20070256477, | |||
| 20080001091, | |||
| 20080009687, | |||
| 20080027245, | |||
| 20080086042, | |||
| 20080154101, | |||
| 20080154107, | |||
| 20080183061, | |||
| 20080188722, | |||
| 20080188725, | |||
| 20080287761, | |||
| 20080296155, | |||
| 20080305009, | |||
| 20080305506, | |||
| 20080311675, | |||
| 20080312560, | |||
| 20090005266, | |||
| 20090018418, | |||
| 20090018426, | |||
| 20090048430, | |||
| 20090061528, | |||
| 20090062696, | |||
| 20090076336, | |||
| 20090081803, | |||
| 20090082566, | |||
| 20090088329, | |||
| 20090098052, | |||
| 20090104714, | |||
| 20090112075, | |||
| 20090143659, | |||
| 20090171381, | |||
| 20090177143, | |||
| 20090182217, | |||
| 20090192416, | |||
| 20090196864, | |||
| 20090200620, | |||
| 20090228068, | |||
| 20090264719, | |||
| 20090275815, | |||
| 20090324945, | |||
| 20100160861, | |||
| 20100173065, | |||
| 20100274110, | |||
| 20100279424, | |||
| 20100292617, | |||
| 20100312483, | |||
| 20110077477, | |||
| 20110105866, | |||
| 20110152658, | |||
| 20110171742, | |||
| 20110224516, | |||
| 20110236989, | |||
| 20110263953, | |||
| 20120053427, | |||
| 20120116191, | |||
| 20120208286, | |||
| 20120282412, | |||
| 20130267801, | |||
| 20130267802, | |||
| 20130287631, | |||
| CN85108331, | |||
| D388418, | Mar 18 1996 | EMC Corporation | Computer screen with an icon |
| D525632, | Jul 12 2004 | Sevic System AG | Set of icons for a portion of an automotive windshield display |
| D544871, | Dec 02 2005 | Samsung Electronics Co., Ltd. | Generated image for a portable telephone |
| D550242, | Nov 10 2005 | Sony Corporation | Computer generated image for a display panel or screen |
| D550245, | Nov 10 2005 | Sony Corporation | Computer generated image for a display panel or screen |
| D559264, | Nov 10 2005 | Sony Corporation | Computer generated image for a display panel or screen |
| D560224, | Apr 17 2006 | Samsung Electronics Co., Ltd.; SAMSUNG ELECTRONICS CO , LTD | Telephone with video display |
| D580950, | Jun 15 2007 | Microsoft Corporation | Icon for a portion of a display screen |
| D582939, | Oct 12 2006 | Bystronic Laser AG | Printed material and icon for computer display, electronic screen |
| D592223, | Oct 12 2006 | Bystronic Laser AG | Printed material and icon for computer display, electronic screen |
| D610065, | Dec 19 2008 | Dr. Ing. h.c. F. Porsche Aktiengesellschaft | Automobile wheel |
| D626143, | Feb 06 2007 | MEDTRONIC MINIMED, INC | Computer-generated icon for a blood glucose display |
| DE19502183, | |||
| DE19820808, | |||
| DE3036868, | |||
| DE3509262, | |||
| DE3720736, | |||
| EP7607230001, | |||
| EP73558, | |||
| EP147168, | |||
| EP596700, | |||
| EP617977, | |||
| EP758451, | |||
| EP2054476, | |||
| EP2122361, | |||
| EP2147003, | |||
| EP2162057, | |||
| EP2217316, | |||
| EP2222686, | |||
| EP2438152, | |||
| EP2496139, | |||
| FR2350831, | |||
| FR2624007, | |||
| GB1123094, | |||
| GB1447163, | |||
| GB2048682, | |||
| JP2003262613, | |||
| JP2005287762, | |||
| JP2005315871, | |||
| JP2009544729, | |||
| JP2010507711, | |||
| JP2010517693, | |||
| JP2010518397, | |||
| JP2010526599, | |||
| JP2010527010, | |||
| JP2010535903, | |||
| JP2011504399, | |||
| JP2011511755, | |||
| JP2012529060, | |||
| JP3052936, | |||
| JP5017377, | |||
| JP5368249, | |||
| JP54013347, | |||
| JP54111363, | |||
| JP54155856, | |||
| JP56116752, | |||
| JP56116754, | |||
| JP58162921, | |||
| JP6016859, | |||
| RE31879, | Feb 25 1976 | Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. | Method and arrangement for measuring the concentration of gases |
| RE32514, | Jun 14 1982 | Eastman Kodak Company | Polymer compositions having a low coefficient of friction |
| WO2048, | |||
| WO13003, | |||
| WO43536, | |||
| WO120019, | |||
| WO160248, | |||
| WO246752, | |||
| WO3034047, | |||
| WO3060464, | |||
| WO2004054438, | |||
| WO2004099778, | |||
| WO2005065241, | |||
| WO2005090014, | |||
| WO2006044973, | |||
| WO2007059311, | |||
| WO2007067743, | |||
| WO2007105140, | |||
| WO2008001091, | |||
| WO2008014280, | |||
| WO2008049932, | |||
| WO2008072338, | |||
| WO2008097747, | |||
| WO2008098011, | |||
| WO2008098087, | |||
| WO2008137604, | |||
| WO2008141241, | |||
| WO2008141243, | |||
| WO2009009756, | |||
| WO2009018426, | |||
| WO2009021057, | |||
| WO2009067626, | |||
| WO2009129186, | |||
| WO2010123972, | |||
| WO2010141888, | |||
| WO2011041546, | |||
| WO2011056274, | |||
| WO2011075710, | |||
| WO2011075711, | |||
| WO2011084713, | |||
| WO2011097586, | |||
| WO2011112030, | |||
| WO2011137178, | |||
| WO2013033076, | |||
| WO2013049068, | |||
| WO8700920, | |||
| WO88004415, | |||
| WO9109312, | |||
| WO9219150, | |||
| WO9316406, | |||
| WO9410553, | |||
| WO9530148, | |||
| WO96022798, | |||
| WO9622730, | |||
| WO97020530, | |||
| WO97037713, | |||
| WO97048437, | |||
| WO9808554, | |||
| WO9958053, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Aug 07 2014 | Medtronic MiniMed, Inc. | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| May 20 2021 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Date | Maintenance Schedule |
| Dec 12 2020 | 4 years fee payment window open |
| Jun 12 2021 | 6 months grace period start (w surcharge) |
| Dec 12 2021 | patent expiry (for year 4) |
| Dec 12 2023 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 12 2024 | 8 years fee payment window open |
| Jun 12 2025 | 6 months grace period start (w surcharge) |
| Dec 12 2025 | patent expiry (for year 8) |
| Dec 12 2027 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 12 2028 | 12 years fee payment window open |
| Jun 12 2029 | 6 months grace period start (w surcharge) |
| Dec 12 2029 | patent expiry (for year 12) |
| Dec 12 2031 | 2 years to revive unintentionally abandoned end. (for year 12) |